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A B S T R A C T
Background
As part of liver transplantation, immunosuppression (suppressing the host immunity) is given to prevent graft rejections resulting from
the immune response of the body against transplanted organ or tissues from a different person whose tissue antigens are not compatible
with those of the recipient. The optimal maintenance immunosuppressive regimen after liver transplantation remains uncertain.
Objectives
To assess the comparative benefits and harms of different maintenance immunosuppressive regimens in adults undergoing liver trans-
plantation through a network meta-analysis and to generate rankings of the different immunosuppressive regimens according to their
safety and efficacy.
Search methods
We searched CENTRAL, MEDLINE, Embase, Science Citation Index Expanded, World Health Organization International Clinical
Trials Registry Platform, and trials registers until October 2016 to identify randomised clinical trials on immunosuppression for liver
transplantation.
Selection criteria
We included only randomised clinical trials (irrespective of language, blinding, or publication status) in adult participants undergoing
liver transplantation (or liver retransplantation) for any reason. We excluded trials in which participants had undergone multivisceral
transplantation or participants with established graft rejections. We considered any of the various maintenance immunosuppressive
regimens compared with each other.
Data collection and analysis
We performed a network meta-analysis with OpenBUGS using Bayesian methods and calculated the odds ratio, rate ratio, and hazard
ratio (HR) with 95% credible intervals (CrI) based on an available-case analysis, according to National Institute of Health and Care
Excellence Decision Support Unit guidance.
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Main results
We included a total of 26 trials (3842 participants) in the review, and 23 trials (3693 participants) were included in one or more
outcomes in the review. The vast majority of the participants underwent primary liver transplantation. All of the trials were at high risk
of bias, and all of the evidence was of low or very low quality. In addition, because of sparse data involving trials at high risk of bias, it
is not possible to entirely rely on the results of the network meta-analysis. The trials included mainly participants undergoing primary
liver transplantation of varied aetiologies. The follow-up in the trials ranged from 3 to 144 months. The most common maintenance
immunosuppression used as a control was tacrolimus. There was no evidence of difference in mortality (21 trials; 3492 participants) or
graft loss (15 trials; 2961 participants) at maximal follow-up between the different maintenance immunosuppressive regimens based on
the network meta-analysis. In the direct comparison, based on a single trial including 222 participants, tacrolimus plus sirolimus had
increased mortality (HR 2.76, 95% CrI 1.30 to 6.69) and graft loss (HR 2.34, 95% CrI 1.28 to 4.61) at maximal follow-up compared
with tacrolimus. There was no evidence of differences in the proportion of people with serious adverse events (1 trial; 719 participants),
proportion of people with any adverse events (2 trials; 940 participants), renal impairment (8 trials; 2233 participants), chronic kidney
disease (1 trial; 100 participants), graft rejections (any) (16 trials; 2726 participants), and graft rejections requiring treatment (5 trials;
1025 participants) between the different immunosuppressive regimens. The network meta-analysis showed that the number of adverse
events was lower with cyclosporine A than with many other immunosuppressive regimens (12 trials; 1748 participants), and the risk
of retransplantation (13 trials; 1994 participants) was higher with cyclosporine A than with tacrolimus (HR 3.08, 95% CrI 1.13 to
9.90). None of the trials reported number of serious adverse events, health-related quality of life, or costs.
Funding: 14 trials were funded by pharmaceutical companies who would benefit from the results of the trial; two trials were funded by
parties who had no vested interest in the results of the trial; and 10 trials did not report the source of funding.
Authors’ conclusions
Based on low-quality evidence from a single small trial from direct comparison, tacrolimus plus sirolimus increases mortality and graft
loss at maximal follow-up compared with tacrolimus. Based on very low-quality evidence from network meta-analysis, we found no
evidence of difference between different immunosuppressive regimens.We found very low-quality evidence from network meta-analysis
and low-quality evidence from direct comparison that cyclosporine A causes more retransplantation compared with tacrolimus. Future
randomised clinical trials should be adequately powered; performed in people who are generally seen in the clinic rather than in highly
selected participants; employ blinding; avoid postrandomisation dropouts or planned cross-overs; and use clinically important outcomes
such as mortality, graft loss, renal impairment, chronic kidney disease, and retransplantation. Such trials should use tacrolimus as one
of the control groups. Moreover, such trials ought to be designed in such a way as to ensure low risk of bias and low risks of random
errors.
P L A I N L A N G U A G E S U M M A R Y
Medical interventions to prevent graft rejection after liver transplantation
Background
Liver transplantation is the main treatment option for people with severe advanced liver disease. When organs or tissues are transplanted
from one person (organ donor) to another (organ recipient), the body of the organ recipient identifies the donor organ (or graft) as
a foreign body and mounts a response against it in a way similar to the natural body defence mechanism against infections (immune
response). This can lead to graft rejection and graft loss resulting in death of the organ recipient. Various medical interventions are used
either alone or in combination (immunosuppressive regimen) to prevent graft rejections. The combination of interventions used in the
first few months after liver transplantation (induction immunosuppressive regimen) often differs from the combination used for the
rest of the patient’s life (maintenance immunosuppression). It is unclear which immunosuppressive regimen after liver transplantation
is the best. We sought to identify the best maintenance immunosuppressive regimen by searching for existing studies on the topic.
We included all randomised clinical trials reported until October 2016. We included only trials of participants who had previously
undergone liver transplantation. We excluded trials of participants who had undergone multi-organ transplantation (e.g. liver and
kidney transplantations) or participants with established graft rejections. Apart from using standard Cochrane methods, which allow
comparison of only two interventions at a time (direct comparison), we also employed advanced methods that allow comparison of the
many different interventions individually compared in the trials (network meta-analysis).
Study characteristics
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We identified 26 randomised clinical trials with a total of 3842 participants. Of these, 23 randomised clinical trials (3693 participants)
provided information for one or more outcomes. The trials mainly included participants undergoing liver transplantation for the first
time, for various reasons.
Funding: 14 trials were funded by pharmaceutical companies who would benefit from the results of the trial; two trials were funded by
parties who had no vested interest in the results of the trial; and 10 trials did not report the source of funding.
Quality of evidence
The overall quality of the evidence was low or very low, and all of the trials were at high risk of bias, which means it is possible that the
conclusions made could overestimate the benefits or underestimate the harms of a given intervention because of the way the trials were
conducted. In addition, because of insufficient information, the results of network meta-analysis are not entirely reliable.
Key results
Several medical drugs were compared in the trials. We found no evidence of difference in the risk of death or graft loss between the
different immunosuppressive regimens based on the network meta-analysis. In the direct comparison, based on a single trial including
222 participants, the risk of death and graft loss was higher with tacrolimus plus sirolimus than with tacrolimus alone. There was
no evidence of differences between the various immunosuppressive regimens in percentage of people who developed serious adverse
events, percentage of people who developed any adverse events, risk of poor kidney function requiring dialysis or kidney transplantation
(kidney dysfunction), prolonged kidney disease, graft rejections requiring treatment, and any graft rejections. The number of adverse
events was lower with cyclosporine A than with many other immunosuppressive regimens. The risk of retransplantation was higher
with cyclosporine A than with tacrolimus. None of the trials reported number of serious adverse events, health-related quality of life,
or costs.
There is significant uncertainty as to the optimal maintenance immunosuppressive regimen after liver transplantation; further well-
designed randomised clinical trials are required. Future trials should be performed in people who are generally seen in the clinic rather
than in highly selected participants and report clinically important outcomes such as death, graft loss, kidney dysfunction, long-term
kidney disease, and retransplantation. Such trials should use tacrolimus as one of the control groups. Moreover, such trials ought to be
designed in such a way as to ensure low risk of bias and low risks of random errors.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
M aintenance immunosuppressive regimens for adults undergoing liver transplantation: a network meta-analysis
Patient or population: people undergoing liver transplantat ion
Settings: tert iary care
Intervention: various intervent ions
Comparison: tacrolimus
Follow-up period: 6 months to 144 months
Interventions Illustrative comparative risks* (95% CrI) Relative effect
(95% CrI)
No. of partici-
pants
(trials)
Quality of
the evidence of
network meta-
analysis
(GRADE)
Assumed risk Corresponding risk
Tacrolimus Var-
ious interven-
tions (based on
direct compari-
son)
Various inter-
ventions
(based on in-
direct compari-
son)
Var-
ious interven-
tions (based on
network meta-
analysis)
Direct compari-
son
Indirect com-
parison
Network meta-
analysis
M ortality at maximal follow-up
Cyclosporine A 154 per 1000 169 per 1000
(86 to 360)
157 per 1000
(17 to 1000)
172 per 1000
(112 to 279)
HR 1.10
(0.56 to 2.34)
Quality of evi-
dence: very low
1,2,4,5
HR 1.02
(0.11 to 13.80)
Quality of evi-
dence: very low
1,2,3,5
HR 1.12
(0.73 to 1.81)
1176
(8 trials)
⊕©©©
very low6
Cyclosporine A
plus azathio-
prine
154 per 1000 202 per 1000
(8 to 4919)
171 per 1000
(105 to 291)
206 per 1000
(85 to 459)
HR 1.31
(0.05 to 31.94)
Quality of evi-
dence: very low
1,4,5
HR 1.11
(0.68 to 1.89)
Quality of evi-
dence: very low
1,2,3,5
HR 1.34
(0.55 to 2.98)
202
(2 trials)
⊕©©©
very low6
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Cyclosporine A
plus azathio-
prine plus glu-
cocorticos-
teroids
154 per 1000 - 1000 per 1000
(52 to 1000)
1000 per 1000
(43 to 1000)
- HR 10.87
(0.34 to 1191.
54)
Quality of evi-
dence: very low
1,2,3,5
HR 9.40
(0.28 to 2375.
59)
No direct com-
parison
⊕©©©
very low6
Cyclosporine A
plus glucocor-
ticosteroids
154 per 1000 - 106 per 1000
(37 to 280)
108 per 1000
(37 to 293)
- HR 0.69
(0.24 to 1.82)
Quality of evi-
dence: very low
1,2,3,5
HR 0.70
(0.24 to 1.90)
No direct com-
parison
⊕©©©
very low6
Cyclosporine A
plus mycophe-
no-
late plus gluco-
corticosteroids
154 per 1000 - 1000 per 1000
(37 to 1000)
1000 per 1000
(25 to 1000)
- HR 14.66
(0.24 to 1988.
23)
Quality of evi-
dence: very low
1,2,3,5
HR 11.01
(0.16 to 3226.
01)
No direct com-
parison
⊕©©©
very low6
Everolimus 154 per 1000 249 per 1000
(112 to 614)
306 per 1000
(62 to 1000)
251 per 1000
(102 to 708)
HR 1.62
(0.73 to 3.99)
Quality of evi-
dence: very low
1,4,5
HR 1.99
(0.40 to 9.40)
Quality of evi-
dence: very low
1,2,3,5
HR 1.63
(0.66 to 4.60)
474
(1 trial)
⊕©©©
very low6
Tacrolimus
plus azathio-
prine
154 per 1000 71 per 1000
(26 to 177)
257 per 1000
(106 to 655)
71 per 1000
(18 to 257)
HR 0.46
(0.17 to 1.15)
Quality of evi-
dence: very low
1,4,5
HR 1.67
(0.69 to 4.25)
Quality of evi-
dence: very low
1,2,3,5
HR 0.46
(0.12 to 1.67)
97
(1 trial)
⊕©©©
very low6
Tacrolimus
plus
everolimus
154 per 1000 220 per 1000
(97 to 521)
266 per 1000
(66 to 1000)
217 per 1000
(68 to 728)
HR 1.43
(0.63 to 3.38)
Quality of evi-
dence: very low
1,4,5
HR 1.73
(0.43 to 10.21)
Quality of evi-
dence: very low
1,2,3,5
HR 1.41
(0.44 to 4.73)
488
(1 trial)
⊕©©©
very low6
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Tacrolimus
plus glucocor-
ticosteroids
154 per 1000 - 83 per 1000
(25 to 305)
92 per 1000
(22 to 354)
- HR 0.54
(0.16 to 1.98)
Quality of evi-
dence: very low
1,2,3,5
HR 0.60
(0.14 to 2.30)
No direct com-
parison
⊕©©©
very low6
Tacrolimus
plus mycophe-
no-
late plus gluco-
corticosteroids
154 per 1000 89 per 1000
(22 to 294)
59 per 1000
(8 to 451)
82 per 1000
(20 to 288)
HR 0.58
(0.14 to 1.91)
Quality of evi-
dence: very low
1,4,5
HR 0.38
(0.05 to 2.93)
Quality of evi-
dence: very low
1,2,3,5
HR 0.53
(0.13 to 1.87)
195
(1 trial)
⊕©©©
very low6
Tacrolimus
plus sirolimus
154 per 1000 425 per 1000
(200 to 1000)
75 per 1000
(22 to 246)
434 per 1000
(123 to 1000)
HR 2.76
(1.30 to 6.69)
Quality of evi-
dence: low1,4
HR 0.49
(0.14 to 1.60)
Quality of evi-
dence: very low
1,2,3,5
HR 2.82
(0.80 to 9.56)
222
(1 trial)
⊕⊕©©
low6
Health- related quality of life
None of the trials reported this outcome.
* The basis for the assumed risk is the mean control group proport ion (15.4%). The corresponding risk (and its 95% credible interval) is based on the assumed risk in the
comparison group and the relative effect of the intervent ion (and its 95% CrI) for dif f erent types of est imates
CrI: credible intervals; HR: hazard rat io
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Risk of bias: trial(s) were at high risk of bias (downgraded by one level).
2Heterogeneity: there were dif ferences in the ef fect est imates obtained by f ixed-ef fect model and random-ef fects model
(downgraded by one level).
3Indirectness: sparse network made up of trials at high risk of bias (downgraded one level).
4Imprecision: small sample size (sample size required to measure 20%relat ive risk reduct ion f rom 15.4%= 3950) (downgraded
by one level).6
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5Imprecision: credible intervals overlapped a clinically signif icant increase or reduct ion and clinically insignif icant increase
or reduct ion (20% relat ive risk increase or reduct ion, i.e. 3.1% absolute increase or decrease f rom 15.4% was considered
clinically signif icant) (downgraded by one level).
6Overall quality of evidence in network meta-analysis: best of direct and indirect comparisons.
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B A C K G R O U N D
Description of the condition
The liver is a complex organ with multiple functions including
carbohydrate metabolism, fat metabolism, protein metabolism,
drug metabolism, synthetic functions, storage functions, diges-
tive functions, excretory functions, and immunological functions
(Read 1972). The liver can be affected by acute or chronic diseases.
Themain causes of chronic liver disease are alcohol abuse and viral
infections such as viral hepatitis B and C (Dam Fialla 2012; Ratib
2014). Other causes include autoimmune hepatitis, primary bil-
iary cirrhosis, primary sclerosing cholangitis, haemochromatosis,
alpha-1 antitrypsin deficiency, non-alcoholic steatohepatitis, and
cryptogenic cirrhosis (cirrhosis of unknown cause) (Dam Fialla
2012; Ratib 2014).
Chronic liver disease caused 10,000 deaths in 2009 in the UK and
36,000 deaths in 2013 in the USA (Davies 2012; CDC 2015).
While the age-standardised mortality due to cirrhosis (advanced
liver fibrosis) has decreased from 18.6 per 100,000 per year to
15.6 per 100,000 per year overall, the proportion of all deaths
caused by cirrhosis is increasing in some countries such as the UK
(Lozano 2012;Murray 2013). Cirrhosis has two phases, an asymp-
tomatic ’compensated cirrhosis’ phase and a ’decompensated cir-
rhosis’ phase characterised by clinical manifestations such as up-
per gastrointestinal bleeding from varices, ascites, encephalopathy,
jaundice, or renal failure (D’Amico 2006). The median survival in
people with compensated liver disease varies and can be more than
10 years, while for people with decompensated liver disease it is
less than two years (D’Amico 2006). The only definitive treatment
for decompensated liver cirrhosis is liver transplantation. Chronic
liver failure is the most common indication for liver transplan-
tation (Graziadei 2016). Other important indications are acute
liver failure and hepatocellular carcinoma (Graziadei 2016). The
median survival after liver transplantation is in excess of 10 years
(Duffy 2010; SRTR 2012; Schoening 2013). There may also be
an improvement in the quality of life of people with chronic liver
disease after liver transplantation (Yang 2014).
Approximately 7000 liver transplantations are carried out in Eu-
rope and 6000 liver transplantations are carried out in the USA
each year (SRTR 2012; ELTR 2017). The majority of the liver
grafts are obtained from cadaveric donors (SRTR 2012; NHSBT
2014). Living-donor liver transplantation is associated with in-
creased complications and retransplantation and constitutes only
a small proportion of liver transplantation (Wan 2014). Pretrans-
plant deaths occur at a rate of 5.8 deaths per 100 waitlist years in
the USA (SRTR 2012), and 12% of people on the UK waiting
list died or became too unwell to be transplanted (NHSBT 2014),
indicating organ shortage necessitating an organ allocation policy.
The Model for End-Stage Liver Disease (MELD) score, which is
calculated based on serum bilirubin levels, creatinine levels, and
International Normalised Ratio (INR) for prothrombin time and
was first reported in 2001 (Kamath 2001), is the current method
of selecting candidates and allocating organs in the USA. A similar
scoring system with the additional parameter of sodium levels is
used to calculate the United Kingdom Model for End-Stage Liver
Disease (UKELD), which is used by individual centres for priori-
tising people for transplantation in the UK (Barber 2011).
Description of the intervention
As part of liver transplantation, immunosuppression (suppressing
the host immunity) is given to prevent graft rejections (Geissler
2009). Graft rejection can be described as an immune response
(either cell-mediated immunity (mediated by cytotoxic T cells) or
humoral immunity (antibody-mediated immunity mediated by B
lymphocytes)) of the body against transplanted organ or tissues
from a different person whose tissue antigens are not compatible
with those of the recipient (NCBI 2014). Human leukocyte anti-
gen (HLA) typing and matching is not used for organ allocation
in liver transplantation, as there is no evidence of a difference in
graft survival between HLA-matched and HLA-mismatched liver
transplantation (Lan 2010).While transplanted liver grafts are less
prone to graft rejection than other organ transplants, immunosup-
pression is routinely used for recipients of liver transplants (Geissler
2009). Various drugs have been used for immunosuppression, in-
cluding calcineurin inhibitors (cyclosporineA and tacrolimus), an-
timetabolites (mycophenolate mofetil, mycophenolic acid, or aza-
thioprine), mTOR (mammalian target of rapamycin) inhibitors
(sirolimus, everolimus), corticosteroids (methylprednisolone), and
antibody-based therapies (thymoglobulin, antithymocyte glob-
ulin, alemtuzumab, basiliximab, daclizumab) (Haddad 2006;
Geissler 2009; Fairfield 2015). These drugs may be used alone
(usually calcineurin inhibitors or antimetabolites) or can be used in
combination (usually a calcineurin inhibitor and a corticosteroid
or a combination of calcineurin inhibitor, antimetabolite, and cor-
ticosteroid) (Lan 2014). Other combinations, such as calcineurin
inhibitor and antimetabolite; antimetabolite and corticosteroids;
antimetabolite and mTOR inhibitor; and mTOR inhibitor and
corticosteroids may be used (Maheshwari 2006; Herlenius 2010).
Antibodiesmay be used in addition to these interventions or as a re-
placement for corticosteroids (Penninga 2014a; Penninga 2014b).
The main purpose of these combinations is to decrease the adverse
effects of the individual drugs by reduction in dosage and to sup-
press immunity by multiple mechanisms (Geissler 2009). Initial
immunosuppression (induction immunosuppression) often dif-
fers from long-term immunosuppression (maintenance immuno-
suppression) because it is widely believed that graft rejections are
more common during the first few months after liver transplanta-
tion.
Immunosuppression is associated with a variety of adverse effects.
In general, immunosuppression is associated with increased risk of
infections and malignancy (Geissler 2009; Rodriguez-Peralvarez
2014). In addition, the adverse effects of different drugs include
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renal toxicity (calcineurin inhibitors), gastrointestinal adverse ef-
fects (antimetabolites), bone marrow suppression (antimetabo-
lites), hepatic artery thrombosis (mTOR inhibitors), elevated
cholesterol levels (mTOR inhibitors), diabetes (corticosteroids),
hypertension (corticosteroids), osteoporosis (corticosteroids), and
obesity (corticosteroids). Immunosuppression and related mon-
itoring are the major costs associated with liver transplantation,
costing approximately GBP 25,000 in 2003 (Longworth 2003).
How the intervention might work
Ciclosporin inhibits calcineurin, a calcium/calmodulin-depen-
dent phosphatase complex that inhibits the nuclear factor of ac-
tivated T cells (NFAT) from entering the nucleus, an essential
step in the activation of cytotoxic T cells (Geissler 2009). My-
cophenolate mofetil and mycophenolic acid inhibit inosine-5’-
monophosphate dehydrogenase (IMPDH), an important enzyme
necessary for synthesis of guanosine nucleotides, which is in turn
necessary for the growth of the B lymphocytes and T lymphocytes
(Geissler 2009). Sirolimus and everolimus (mTOR inhibitors) in-
hibit mTORC1 (mammalian target of rapamycin complex 1) ac-
tivity, which plays a key role in the proliferation of T cells in re-
sponse to interleukin-2 (Geissler 2009). Corticosteroids inhibit
arachidonic acid metabolism, antigen presentation by dendritic
cells, and interleukin-1 dependent lymphocyte activation by de-
creasing interleukin-1 transcription (Geissler 2009). Thymoglob-
ulin, antithymocyte globulin, and alemtuzumab are antibodies
against lymphocytes (Geissler 2009). Basiliximab and daclizumab
are interleukin-2 antibodies and so suppress T-cell proliferation
(Geissler 2009).
Why it is important to do this review
It is important to provide optimal maintenance immunosuppres-
sion so that the transplanted liver and the person can survive for
the longest time possible. This is particularly important given the
shortage of donor organs. Several maintenance immunosuppres-
sion regimens are available, and the optimal regimen in terms
of clinical effectiveness or cost-effectiveness is unknown. There
have been several Cochrane systematic reviews on immunosup-
pression in liver transplantation (Haddad 2006; Penninga 2012;
Fairfield 2015). There has been no previous network meta-anal-
ysis on maintenance immunosuppressive regimens in people un-
dergoing liver transplantation. Network meta-analysis allows for
a combination of direct evidence and indirect evidence and the
ranking of different interventions in terms of the different out-
comes (Salanti 2011; Salanti 2012). With this systematic review
and network meta-analysis we aimed to provide the best level of
evidence for the role of different maintenance immunosuppressive
regimens in people undergoing liver transplantation.
O B J E C T I V E S
To assess the comparative benefits and harms of different main-
tenance immunosuppressive regimens in adults undergoing liver
transplantation through a network meta-analysis and to generate
rankings of the different immunosuppressive regimens according
to their safety and efficacy.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We considered only randomised clinical trials for this network
meta-analysis irrespective of language, publication status, or date
of publication. We excluded studies of other design because of
the risk of bias in such studies. Inclusion of indirect observational
evidence could weaken our network meta-analysis, but it can also
be viewed as a strength. It is well established that exclusion of non-
randomised studies increases the focus on potential benefits and
reduces the focus on the risks of serious adverse events and those
of adverse events.
Types of participants
We included randomised clinical trials with adult participants un-
dergoing liver transplantation (or liver retransplantation) for any
reason. We excluded randomised clinical trials in which partici-
pants had undergone multivisceral transplantation, since the im-
munosuppressive regimens may have to be tailored for the other
organ. We also excluded randomised clinical trials that compared
different regimens in treating established graft rejections, as the
main purpose of routine maintenance immunosuppression is to
prevent graft rejection.
Types of interventions
Any of the following possible maintenance immunosuppressive
regimens after liver transplantation compared with each other. As
we anticipated, none of the trials we identified had no immuno-
suppression in one of the intervention groups.
The following are some of the immunosuppressive regimens used
alone or in combination that we considered:
• calcineurin inhibitors (e.g. cyclosporine A and tacrolimus);
• antimetabolites (e.g. mycophenolate mofetil,
mycophenolate, or azathioprine);
• mTOR inhibitors (e.g. sirolimus, everolimus);
• glucocorticosteroids (e.g. methylprednisolone).
The above list is not exhaustive. If we identified immunosuppres-
sive regimens of which we were unaware, we considered them to
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be eligible and included them in the network if they were used
primarily for maintenance immunosuppression after liver trans-
plantation. We reported the findings for these interventions in the
Results and Discussion sections of the review. We considered only
maintenance immunosuppressive for this review. We performed
a subgroup analysis of trials in which the drug combination used
for induction differed from that of maintenance therapy com-
pared to trials in which the drug combination used for induction
was the same as maintenance therapy (see Subgroup analysis and
investigation of heterogeneity).
We evaluated the plausibility of transitivity assumption (the as-
sumption that the participants included in the different trials with
different immunosuppressive regimens can be considered to be a
part of a multi-arm randomised clinical trial and could potentially
have been randomised to any of the interventions) (Salanti 2012).
In other words, any participant that meets the inclusion criteria is,
in principle, equally likely to be randomised to any of the above el-
igible interventions. This necessitates that information on poten-
tial effect-modifiers such as primary transplantation versus retrans-
plantation and the reasons for liver transplantation should be sim-
ilar across trials. While we acknowledge that the relative effect of
the different interventions may be different in people undergoing
primary liver transplantation and those undergoing retransplan-
tation and be based on different reasons for liver transplantation,
we performed an analysis including all types of participants but
planned to evaluate the treatment effect and ranking of different
interventions in a subgroup analysis of people undergoing primary
liver transplantation and people undergoing retransplantation (see
Subgroup analysis and investigation of heterogeneity). If there was
any concern that the clinical safety and effectiveness were depen-
dent upon whether the participants had undergone primary liver
transplantation or retransplantation or upon the different reasons
for liver transplantation, we planned not to perform a network
meta-analysis on all participant subgroups.
Types of outcome measures
We assessed the comparative benefits and harms (and reported
the relative ranking) of available maintenance immunosuppressive
regimens in people with liver transplantation for the following
outcomes.
Primary outcomes
1. Mortality at maximal follow-up (time to death; maximal
follow-up).
2. Graft loss at maximal follow-up (time to graft loss or death).
3. Adverse events (within three months after cessation of
intervention). Depending on the availability of data, we
attempted to classify adverse events as serious or non-serious. We
defined a non-serious adverse event as any untoward medical
occurrence not necessarily having a causal relationship with the
intervention but resulting in a dose reduction or discontinuation
of intervention (any time after commencement of intervention)
(ICH-GCP 1997). We defined a serious adverse event as any
event that would increase mortality; is life-threatening; requires
hospitalisation; results in persistent or significant disability; is a
congenital anomaly/birth defect; or any important medical event
that might jeopardise the person or require intervention to
prevent it. We used the definition used by study authors for non-
serious and serious adverse events:
i) serious adverse events;
ii) any adverse events;
iii) renal impairment (requiring renal support or renal
transplantation);
iv) chronic kidney disease (as defined by authors).
4. Health-related quality of life as defined in the included
trials using a validated scale such as the EQ-5D or 36-Item Short
Form Health Survey (SF-36) (EuroQol 2014; Ware 2014):
i) short term (up to one year);
ii) medium term (one to five years);
iii) long term (beyond five years).
We considered long-term health-related quality of life more im-
portant than short-term or medium-term health-related quality of
life, although short-term and medium-term health-related quality
of life were also important primary outcomes.
Secondary outcomes
1. Retransplantation (at maximal follow-up).
2. Acute graft rejections (within one year) (Banff criteria if
possible, otherwise as defined by authors) (Demetris 1997):
i) any acute graft rejections;
ii) graft rejections requiring treatment (additional
immunosuppression or increase in dosage of one or more
components of the immunosuppression regimen).
3. Costs (maximal follow-up). We planned to include costs
related to the drugs and monitoring required as a result of the
drugs.
Search methods for identification of studies
Electronic searches
We searched the Cochrane Central Register of Controlled Tri-
als (CENTRAL) in the Cochrane Library, MEDLINE (OvidSP),
Embase (OvidSP), and Science Citation Index Expanded (Web
of Knowledge) from inception to 26th October 2016 for ran-
domised clinical trials comparing two or more of the above in-
terventions without applying any language restrictions (Royle
2003). We searched for all possible comparisons formed by the
interventions of interest. To identify further ongoing or com-
pleted trials, we also searched the World Health Organization
International Clinical Trials Registry Platform (apps.who.int/
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trialsearch/), which searches various trial registers, including
ISRCTN and ClinicalTrials.gov. Appendix 1 shows the search
strategies that we used and the time spans of the searches.
Searching other resources
We searched the references of the identified trials and the existing
Cochrane reviews on immunosuppression to identify additional
trials for inclusion.
Data collection and analysis
Selection of studies
Two review authors (KGandMRorMG) independently identified
the trials for inclusion by screening the titles and abstractsseeking
full-text articles for any references identified by at least one of
the review authors for potential inclusion. We selected trials for
inclusion based on the full-text articles. The excluded full-text
references with reasons for their exclusion are provided in the
Characteristics of excluded studies table. We also planned to list
any ongoing trials identified primarily through the search of the
clinical trial registers for further follow-up. Any discrepancies were
resolved through discussion.
Data extraction and management
Two review authors (KG andMRorMG) independently extracted
the following data.
• Outcome data (for each outcome and for each intervention
group whenever applicable):
◦ number of participants randomised;
◦ number of participants included for the analysis;
◦ number of participants with events for binary
outcomes, mean and standard deviation for continuous
outcomes, number of events for count outcomes, and number of
participants with events and the mean follow-up period for time-
to-event outcomes;
◦ definition of outcomes or scale used if appropriate.
• Data on potential effect modifiers:
◦ participant characteristics such as age, sex,
comorbidities, proportion of participants undergoing liver
transplantation for various reasons, and proportion of
participants undergoing retransplantation;
◦ details of the intervention and control (including dose,
frequency, and duration) such as additional intervention for
prevention of recurrence of disease that required transplantation,
e.g. antiviral preparations for people who had undergone liver
transplantation for chronic hepatitis C;
◦ length of follow-up;
◦ risk of bias (Assessment of risk of bias in included
studies).
• Other data:
◦ year and language of publication;
◦ country in which the participants were recruited;
◦ year(s) in which the trial was conducted;
◦ inclusion and exclusion criteria;
◦ follow-up time points of the outcome.
If available, we planned to obtain separate data for participants un-
dergoing liver transplantation for different causes.We also planned
to obtain separate data for participants undergoing primary liver
transplantation (first liver transplantation) and those undergoing
retransplantation if this information was available. We contacted
the trial authors in the case of unclear or missing information. If
there was any doubt as to whether trials shared the same partic-
ipants, completely or partially (by identifying common authors
and centres), we attempted to contact the trial authors to clarify
whether the trial report was duplicated. Any differences in opinion
were resolved through discussion.
Assessment of risk of bias in included studies
We followed the guidance in theCochrane Handbook for Systematic
Reviews of Interventions and described in the Cochrane Hepato-
Biliary Group Module to assess the risk of bias in included trials
(Higgins 2011; Gluud 2016). Specifically, we assessed the risk of
bias in included trials for the following domains using themethods
below (Schulz 1995; Moher 1998; Kjaergard 2001; Wood 2008;
Savovi 2012a; Savovi 2012b; Lundh 2017).
Allocation sequence generation
• Low risk of bias: the study authors performed sequence
generation using computer random number generation or a
random number table. Drawing lots, tossing a coin, shuffling
cards, and throwing dice were adequate if performed by an
independent person not otherwise involved in the study.
• Unclear risk of bias: the study authors did not specify the
method of sequence generation.
• High risk of bias: the sequence generation method was not
random. We planned to only include such studies for assessment
of harms.
Allocation concealment
• Low risk of bias: the participant allocations could not have
been foreseen in advance of, or during, enrolment. A central and
independent randomisation unit controlled allocation. The
investigators were unaware of the allocation sequence (e.g. if the
allocation sequence was hidden in sequentially numbered,
opaque, and sealed envelopes).
• Unclear risk of bias: the study authors did not describe the
method used to conceal the allocation so that the intervention
allocations may have been foreseen before, or during, enrolment.
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• High risk of bias: it is likely that the investigators who
assigned the participants knew the allocation sequence. We
planned to only include such studies for assessment of harms.
Blinding of participants and personnel
• Low risk of bias: any of the following: no blinding or
incomplete blinding, but the review authors judged that the
outcome was not likely to be influenced by lack of blinding; or
blinding of participants and key study personnel ensured, and it
was unlikely that the blinding could have been broken.
• Unclear risk of bias: any of the following: insufficient
information to permit judgement of ’low risk’ or ’high risk’; or
the trial did not address this outcome.
• High risk of bias: any of the following: no blinding or
incomplete blinding, and the outcome was likely to be
influenced by lack of blinding; or blinding of key study
participants and personnel attempted, but likely that the
blinding could have been broken, and the outcome was likely to
be influenced by lack of blinding.
Blinded outcome assessment
• Low risk of bias: any of the following: no blinding of
outcome assessment, but the review authors judged that the
outcome measurement was not likely to be influenced by lack of
blinding; or blinding of outcome assessment ensured, and
unlikely that the blinding could have been broken.
• Unclear risk of bias: any of the following: insufficient
information to permit judgement of ’low risk’ or ’high risk’; or
the trial did not address this outcome.
• High risk of bias: any of the following: no blinding of
outcome assessment, and the outcome measurement was likely
to be influenced by lack of blinding; or blinding of outcome
assessment, but likely that the blinding could have been broken,
and the outcome measurement was likely to be influenced by
lack of blinding.
Incomplete outcome data
• Low risk of bias: missing data were unlikely to make
treatment effects depart from plausible values. The study used
sufficient methods, such as multiple imputation, to handle
missing data.
• Unclear risk of bias: there was insufficient information to
assess whether missing data in combination with the method
used to handle missing data were likely to induce bias on the
results.
• High risk of bias: the results were likely to be biased due to
missing data.
Selective outcome reporting
• Low risk of bias: the trial reported the following predefined
outcomes: at least one of the outcomes related to the main reason
for immunosuppression, namely, mortality or graft loss at
maximal follow-up along with intervention-related adverse
events. If the original trial protocol was available, the outcomes
should have been those called for in that protocol. If the trial
protocol was obtained from a trial registry (e.g.
ClinicalTrials.gov), the outcomes sought should have been those
enumerated in the original protocol if the trial protocol was
registered before or at the time that the trial was begun. If the
trial protocol was registered after the trial was begun, those
outcomes were not considered to be reliable.
• Unclear risk of bias: not all predefined, or clinically relevant
and reasonably expected, outcomes were reported fully, or it was
unclear whether data on these outcomes were recorded or not.
• High risk of bias: one or more predefined or clinically
relevant and reasonably expected outcomes were not reported,
despite the fact that data on these outcomes should have been
available and even recorded.
For-profit bias
• Low risk of bias: the trial appeared to be free of industry
sponsorship or other type of for-profit support that could
manipulate the trial design, conductance, or results of the trial.
• Uncertain risk of bias: the trial may or may not have been
free of for-profit bias, as no information on clinical trial support
or sponsorship was provided.
• High risk of bias: the trial was sponsored by industry or
received other type of for-profit support.
Other bias
• Low risk of bias: the trial appeared to be free of other
components that could put it at risk of bias (e.g. inappropriate
control or dose or administration of control, baseline differences,
early stopping).
• Uncertain risk of bias: the trial may or may not have been
free of other components that could put it at risk of bias.
• High risk of bias: there were other factors in the trial that
could put it at risk of bias (e.g. baseline differences, early
stopping).
We considered a trial to be at low risk of bias if we assessed the
trial to be at low risk of bias across all domains. Otherwise, we
considered trials to be at high risk of bias.
Measures of treatment effect
Relative treatment effects
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For dichotomous variables (e.g. proportion of participants with
serious adverse events or any adverse events), we calculated the
odds ratio (OR) with 95% credible interval (CrI) (or Bayesian
confidence interval) (Severini 1993). For continuous variables
(e.g. health-related quality of life reported on the same scale), we
planned to calculate the mean difference (MD) with 95% Crl.
We planned to use standardised mean difference (SMD) values
with 95% Crl for health-related quality of life if included trials
use different scales. For count outcomes (e.g. number of adverse
events and serious adverse events), we calculated the rate ratio RR
with 95% Crl. For time-to-event data (e.g. mortality at maximal
follow-up, graft loss at maximal follow-up), we used hazard ratio
(HR) with 95% Crl.
Relative ranking
We estimated the ranking probabilities for all interventions of be-
ing at each possible rank for each intervention. We then obtained
the surface under the cumulative ranking curve (SUCRA) (cumu-
lative probability) and rankogram (Salanti 2011; Chaimani 2013).
Unit of analysis issues
The unit of analysis was the participant undergoing liver trans-
plantation according to the intervention group to which the par-
ticipant was randomly assigned.
Cluster randomised clinical trials
As expected, we found no cluster randomised clinical trials. Had
we found them, we would have included them provided that the
effect estimate adjusted for cluster correlation was available.
Cross-over randomised clinical trials
As expected, we found no cross-over randomised clinical trials.
Had we identified any, we planned to only include the outcomes
after the period of first intervention since immunosuppressive reg-
imens can potentially have a residual effect.
Trials with multiple intervention groups
We collected data for all trial intervention groups that met the
inclusion criteria. The codes for analysis we used account for the
correlation between the effect sizes from studies with more than
two groups.
Dealing with missing data
We performed an intention-to-treat analysis whenever possible
(Newell 1992); otherwise, we used the data that were available
to us (e.g. a trial may have reported only per-protocol analysis
results). As such ’per-protocol’ analyses may be biased, we planned
to conduct best-worst case scenario analysis (good outcome in
intervention group and bad outcome in control group) and worst-
best case scenario analysis (bad outcome in intervention group and
good outcome in control group) as sensitivity analyses whenever
possible.
For continuous outcomes, we planned to impute the standard
deviation from P values according to guidance in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
If the data were likely to be normally distributed, we planned to
use themedian for meta-analysis when themean was not available.
If it was not possible to calculate the standard deviation from the
P value or the confidence intervals, we planned to impute the
standard deviation using the largest standard deviation in other
trials for that outcome. This form of imputation can decrease the
weight of the study for calculation of mean differences and may
bias the effect estimate to no effect for calculation of standardised
mean differences (Higgins 2011).
Assessment of heterogeneity
We assessed clinical andmethodological heterogeneity by carefully
examining the characteristics and design of included trials. We
planned to assess the presence of clinical heterogeneity by compar-
ing effect estimates in different reasons for liver transplantation,
primary liver transplantation or retransplantation, different drugs
from the class, and doses of the immunosuppressive regimen. Dif-
ferent study designs and risk of bias can contribute to method-
ological heterogeneity.
We assessed statistical heterogeneity by comparing the results of
the fixed-effectmodelmeta-analysis and the random-effectsmodel
meta-analysis, between-study standard deviation (tau2 and com-
paring this with values reported in study of the distribution of
between-study heterogeneity) (Turner 2012), and by calculating
I2 (using Stata/SE 14.2). If we identified substantial heterogene-
ity, that is clinical, methodological, or statistical, we explored and
addressed the heterogeneity in a subgroup analysis (see Subgroup
analysis and investigation of heterogeneity section).
Assessment of transitivity across treatment
comparisons
We assessed the assumption of transitivity by comparing the dis-
tribution of the potential effect modifiers (clinical: primary trans-
plantation or retransplantation, reasons for liver transplantation;
methodological: risk of bias, year of randomisation, duration of
follow-up) across the different pairwise comparisons.
Assessment of reporting biases
For the networkmeta-analysis, we judged the reporting bias by the
completeness of the search (i.e. searching various databases and
including conference abstracts), as we could find no meaningful
order to perform a comparison-adjusted funnel plot (i.e. there was
no specific change in the risk of bias in the studies, sample size, or
the control group used over time) (Chaimani 2012).
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Data synthesis
Methods for indirect and mixed comparisons
We conducted network meta-analyses to compare multiple in-
terventions simultaneously for each of the primary and sec-
ondary outcomes. Network meta-analysis combines direct evi-
dence within trials and indirect evidence across trials (Mills 2012).
We obtained a network plot to ensure that the trials were con-
nected by interventions using Stata/SE 14.2 (Chaimani 2013).We
excluded any trials that were not connected to the network. We
conducted a Bayesian network meta-analysis using the Markov
chain Monte Carlo method in OpenBUGS 3.2.3 as per guid-
ance from the National Institute for Health and Care Excellence
(NICE) Decision Support Unit (DSU) documents (Dias 2016).
We modelled the treatment contrast (i.e. log odds ratio for binary
outcomes, mean difference or standardised mean difference for
continuous outcomes, log rate ratio for count outcomes, and log
hazard ratio for time-to-event outcomes) for any two interventions
(’functional parameters’) as a function of comparisons between
each individual intervention and an arbitrarily selected reference
group (’basic parameters’) using appropriate likelihood functions
and links (Lu 2006b). We used binomial likelihood and logit link
for binary outcomes, Poisson likelihood and log link for count
outcomes, binomial likelihood and complementary log-log link
for time-to-event outcomes, and planned to use normal likelihood
and identity link for continuous outcomes. We used tacrolimus
as the reference group. We performed a fixed-effect model and
random-effects model for the network meta-analysis. We have re-
ported both models for comparison with the reference group in
a forest plot. For each pairwise comparison in a table, we have
reported the fixed-effect model if the two models reported similar
results; otherwise, we reported the more conservative model.
We used a hierarchical Bayesian model using three different initial
values, employing codes provided by NICE DSU (Dias 2016).
We used a normal distribution with large variance (10,000) for
treatment effect priors (vague or flat priors). For the random-ef-
fects model, we used a prior distributed uniformly (limits: 0 to 5)
for between-trial standard deviation but assumed similar between-
trial standard deviation across treatment comparisons (Dias 2016).
We used a ’burn-in’ of 5000 simulations, checked for convergence
visually, and ran the models for another 10,000 simulations to ob-
tain effect estimates. If we did not obtain convergence, we planned
to increase the number of simulations for ’burn-in’. If we still did
not obtain convergence, we planned to use alternate initial values
and priors employingmethods suggested by vanValkenhoef 2012.
We also estimated the probability that each intervention ranks at
one of the possible positions using the NICE DSU codes (Dias
2016).
Assessment of inconsistency
We assessed inconsistency (statistical evidence of the violation of
transitivity assumption) by fitting both an inconsistency model
and a consistency model. We used the inconsistency models em-
ployed in the NICE DSU manual, as we used common between-
study standard deviation (Dias 2014). In addition, we used design-
by-treatment full interaction model and IF (inconsistency factor)
plots to assess inconsistency (Higgins 2012; Chaimani 2013). In
the presence of inconsistency, we planned to assess whether the
inconsistency was due to clinical or methodological heterogene-
ity by performing separate analyses for each of the different sub-
groups mentioned in the Subgroup analysis and investigation of
heterogeneity section.
If there was evidence of inconsistency, we planned to identify areas
in the network where substantial inconsistency might be present
in terms of clinical and methodological diversities between trials
and, when appropriate, limit network meta-analysis to a more
compatible subset of trials.
Direct comparison
We performed the direct comparisons using the same codes and
the same technical details.
Calculation of required information size and Trial Sequential
Analysis
For calculation of the required information size, see Appendix 2.
We performed Trial Sequential Analysis to control the risk of ran-
dom errors when at least two trials were included for the com-
parison of other interventions versus tacrolimus for the outcomes
mortality at maximal follow-up and health-related quality of life,
the two outcomes that determine whether the intervention should
be given (Wetterslev 2008; Thorlund 2011; TSA 2011;Wetterslev
2017). We used an alpha error as per guidance of Jakobsen 2014,
power of 90% (beta error of 10%), a relative risk reduction of
20%, a control group proportion observed in the trials, and the
heterogeneity observed in the meta-analysis. As the only outcome
was mortality at maximal follow-up, which is a time-to-event out-
come, we performed the Trial Sequential Analysis using Stata/SE
14.2, employing methods suggested by Miladinovic 2013.
Subgroup analysis and investigation of heterogeneity
Weplanned to assess the differences in the effect estimates between
the following subgroups usingmeta-regression with the help of the
codes provided in NICEDSU guidance if we included a sufficient
number of trials (Dias 2012a). We planned to use the following
trial-level covariates for meta-regression.
• Trials at low risk of bias compared to trials at high risk of
bias.
• Different reasons for undergoing liver transplantation.
• Primary liver transplantation compared to
retransplantation.
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• Different drugs from the class (cyclosporine A compared to
tacrolimus).
• An additional drug used for induction compared to no
additional drug used for induction (post hoc).
We calculated a single common interaction term when applicable
(Dias 2012a). If the 95% credible intervals of the interaction term
did not overlap zero, we considered this statistically significant.
Sensitivity analysis
If a trial reported only per-protocol analysis results, we planned
to re-analyse the results using the best-worst case scenario and
worst-best case scenario analyses as sensitivity analyses whenever
possible.
Presentation of results
We presented the effect estimates with 95% CrI for each pairwise
comparison calculated from the direct comparisons and network
meta-analysis. We also presented the cumulative probability of the
treatment ranks (i.e. the probability that the intervention is within
the top two, the probability that the intervention is within the top
three, etc.) in graphs (SUCRA) (Salanti 2011). We also plotted
the probability that each intervention was best, second best, third
best, etc. for each of the different outcomes (rankograms), which
are generally considered more informative (Salanti 2011; Dias
2012b).
We presented ’Summary of findings’ tables for mortality. In
Summary of findings for the main comparison, we followed the
approach suggested by Puhan and colleagues (Puhan 2014). First,
we calculated the direct and indirect effect estimates and95%cred-
ible intervals using the node-splitting approach (Dias 2010), that
is calculated the direct estimate for each comparison by includ-
ing only trials in which there was direct comparison of interven-
tions and the indirect estimate for each comparison by excluding
the trials in which there was direct comparison of interventions.
Next we rated the quality of direct and indirect effect estimates
using GRADE methodology, which takes into account the risk of
bias, inconsistency, directness of evidence, imprecision, and pub-
lication bias (Guyatt 2011). We then presented the estimates of
the network meta-analysis and rated the quality of network meta-
analysis effect estimates as the best quality of evidence between the
direct and indirect estimates (Puhan 2014). In addition, we have
presented information on the number of trials and participants as
per the standard ’Summary of findings’ table.
R E S U L T S
Description of studies
Results of the search
We identified 5939 references through electronic searches ofCEN-
TRAL (n = 703), MEDLINE (n = 2985), Embase (n = 1357),
Science Citation Index Expanded (n = 824), World Health Or-
ganization International Clinical Trials Registry Platform (n = 6),
and ClinicalTrials.gov (n = 64). After removing 1603 duplicates,
we obtained 4336 references. We then excluded 4075 clearly ir-
relevant references through screening titles and reading abstracts
and retrieved 261 references for further assessment. We identi-
fied no references through scanning reference lists of the identified
randomised trials. We excluded 171 references (110 studies) for
the reasons stated in the Characteristics of excluded studies table.
Two ongoing trials did not report any interim data (Simone 2014;
Nashan 2015). A total of 88 references (describing 26 trials) met
the inclusion criteria. The reference flow is summarised in the
study flow diagram (Figure 1).
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Figure 1. Study flow diagram.
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Included studies
A total of 26 trials involving 3842 participants met the inclusion
criteria for and were included in this review. Three trials did not
contribute any information for this review (Fernandez-Miranda
1998; Pham 1998; Baiocchi 2006), leaving a total of 3693 partic-
ipants included in one or more outcomes in the review (after pos-
trandomisation dropouts). The mean or median age of the partic-
ipants ranged from 42 years to 55 years in the trials that reported
this information. The proportion of females ranged from 28.1%
to 58.7% in the trials that reported this information. Only one
trial reported including participants undergoing retransplantation
(Greig 2003). The proportion of participants who had undergone
primary transplantation was more than 95% in all trials (Greig
2003). Three trials reported only participants who had undergone
transplantation for chronic hepatitis C virus decompensated cir-
rhosis (Zervos 1998;Martin 2004;Manousou 2014). The remain-
ing trials included participants with varied indications for liver
transplantation. One trial was a three-intervention group trial (De
Simone 2012). The remaining trials had two intervention groups.
The interventions, controls, number of included participants, and
reported follow-up period for the different trials are provided in
Table 1.
Transitivity assumption
Table 2 contains a list potential modifiers in the trials arranged ac-
cording to comparisons. As seen from the table, there was variabil-
ity in the reasons for transplant, period of recruitment, and follow-
up in the trials, but these do not appear to vary by comparison, so
the transitivity assumption appears reasonable. There were also no
specific clinical reasons (based on inclusion and exclusion criteria
listed in the Characteristics of included studies) to suggest that
the type of participants under one comparison would be different
from the type of participants in other comparisons.
Source of funding
Fourteen trials were funded by pharmaceutical companies who
would benefit from the results of the trial (Porayko 1994; Fisher
1998; Sterneck 2000; Chen 2002; O’Grady 2002; Greig 2003;
Martin 2004; Pageaux 2004; Jonas 2005; Shenoy 2008; De
Simone 2012; Pelletier 2013; Asrani 2014; Manousou 2014); two
trials were funded by parties who had no vested interest in the re-
sults of the trial (Fung 1991; Boudjema 2011); and the remaining
10 trials did not report the source of funding.
Excluded studies
None of the excluded studies met the inclusion criteria. The rea-
sons for exclusion are provided in the Characteristics of excluded
studies.
Risk of bias in included studies
The risk of bias is summarised in Figure 2, Figure 3, and Table 3.
As none of the trials were at low risk of bias in all domains, we
considered all trials to be at high risk of bias.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Eight trials were at low risk of bias due to random sequence gen-
eration (Fung 1991; Jain 2001; O’Grady 2002; Martin 2004;
Boudjema 2011; Cholongitas 2011; Asrani 2014; Manousou
2014); the remaining trials were at unclear risk of bias due to ran-
dom sequence generation. Seven trials were at low risk of bias due
to allocation concealment (Fung 1991; Jain 2001; O’Grady 2002;
Martin 2004; Boudjema 2011; Cholongitas 2011; Manousou
2014); the remaining trials were at unclear risk of bias due to al-
location concealment. Overall, seven trials were at low risk of se-
lection bias (Fung 1991; Jain 2001; O’Grady 2002; Martin 2004;
Boudjema 2011; Cholongitas 2011; Manousou 2014).
Blinding
One trial was at low risk of bias due to lack of blinding of par-
ticipants and health professionals and bias due to lack of blind-
ing of outcome assessors (Pageaux 2004); 17 trials were at high
risk of bias due to lack of blinding of participants and health pro-
fessionals and bias due to lack of blinding of outcome assessors
(Porayko 1994; Stegall 1997; Fisher 1998; Pham 1998; Jain 2001;
Loinaz 2001; Chen 2002; O’Grady 2002; Greig 2003; Martin
2004; Jonas 2005; Masetti 2010; Boudjema 2011; Cholongitas
2011; De Simone 2012; Pelletier 2013; Asrani 2014); the remain-
ing trials were at unclear risk of bias due to lack of blinding of par-
ticipants and health professionals and bias due to lack of blinding
of outcome assessors.
Incomplete outcome data
Seventeen trials were at low risk of incomplete outcome data (at-
trition bias) (Porayko 1994; Stegall 1997; Fisher 1998; Jain 2001;
Chen 2002; O’Grady 2002; Greig 2003; Pageaux 2004; Jonas
2005; Baiocchi 2006; Shenoy 2008; Masetti 2010; Boudjema
2011; Cholongitas 2011; De Simone 2012; Pelletier 2013; Asrani
2014); three trials were at high risk of incomplete outcome data
(attrition bias) (Pham 1998; Martin 2004; Manousou 2014); the
remaining trials were at unclear risk of incomplete outcome data
(attrition bias).
Selective reporting
We did not find a published protocol for any of the trials. Six-
teen trials were at low risk of selective reporting (reporting bias)
(Fung 1991; Porayko 1994; Stegall 1997; Belli 1998; Zervos 1998;
Sterneck 2000; Loinaz 2001; O’Grady 2002; Greig 2003; Pageaux
2004; Shenoy 2008; Masetti 2010; Boudjema 2011; De Simone
2012; Pelletier 2013; Asrani 2014); the remaining trials were at
high risk of selecting outcome reporting bias.
Other potential sources of bias
For-profit bias: 14 trials were at high risk of for-profit bias (Porayko
1994; Fisher 1998; Sterneck 2000; Chen 2002; O’Grady 2002;
Greig 2003; Martin 2004; Pageaux 2004; Jonas 2005; Shenoy
2008; De Simone 2012; Pelletier 2013; Asrani 2014; Manousou
2014); two trials were were at low risk of for-profit bias (Fung
1991; Boudjema 2011); the remaining trials were at unclear risk
of for-profit bias.
Three trials were at high risk of other bias (O’Grady 2002; Pageaux
2004;De Simone 2012):O’Grady 2002 was stopped early for ben-
efit; in De Simone 2012, recruitment to one of the intervention
groups was stopped early; and in Pageaux 2004, despite following
participants for 12 months, the authors have presented only the
six-month results, and have excluded two late deaths. The remain-
ing trials were at low risk of other bias.
Effects of interventions
See: Summary of findings for the main comparison
Maintenance immunosuppressive regimens for adults undergoing
liver transplantation: a network meta-analysis
The network plot for all outcomes with more than one trial is
shown in Figure 4. As shown in Figure 4, only two outcomes (mor-
tality at maximal follow-up and graft rejections requiring treat-
ment) have treatment comparisons in which direct and indirect
estimates were available. Although ’closed loops’ are present in
some other outcomes (e.g. graft loss at maximal follow-up, adverse
events (proportion) and renal impairment, and graft rejections
(any)), this was due to a three-armed trial (De Simone 2012). The
data used for the network meta-analysis is available in Appendix
3. The ranking probabilities of different interventions for differ-
ent outcomes in which network meta-analysis was performed is
shown in Table 4. These ranking probabilities are also presented
as figures that show the cumulative probability of being best, sec-
ond best, etc. (SUCRA) and rankogram, which shows the ranking
probability of each intervention at each different rank (best in-
tervention, second best, etc.). These ranking probabilities should
be interpreted with extreme caution because the sparse networks
were made up of trials at high risk of bias.
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Figure 4. The network plots showing the comparisons in which there were at least two trials. The size of
the node (circle) provides a measure of the number of trials in which the particular Intervention was included
as one of the intervention groups. The thickness of the line provides a measure of the number of direct
comparisons between two nodes (Interventions). Only two outcomes (mortality at maximal follow-up and
graft rejections requiring treatment) have treatment comparisons in which direct and indirect estimates were
available. Although ’closed loops’ are present in some other outcomes (e.g. graft loss at maximal follow-up,
adverse events (proportion), renal impairment, and graft rejections (any)), this was due to a trial with three
intervention groups.Abbreviations: Tac = tacrolimus; Cy = cyclosporine A; Myc = mycophenolate; Aza =
azathioprine; Sir = sirolimus; Ever = everolimus; Std = glucocorticosteroids; ˙ = plus
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Mortality at maximal follow-up
The network meta-analysis of mortality at maximal follow-up
included a total of 21 trials (3492 participants) (Fung 1991;
Porayko 1994; Stegall 1997; Belli 1998; Zervos 1998; Sterneck
2000; Jain 2001; Loinaz 2001; Chen 2002; O’Grady 2002; Greig
2003; Martin 2004; Pageaux 2004; Jonas 2005; Shenoy 2008;
Masetti 2010; Boudjema 2011; Cholongitas 2011; De Simone
2012; Asrani 2014; Manousou 2014). In the network meta-anal-
ysis, the between-study standard deviation (τ ) was 0.3949 (τ 2 =
0.1559; lies within the 95% range for all-cause mortality in phar-
macological comparisons) (Turner 2012). We could not estimate
the I2. There was no evidence of inconsistency as evidenced by the
model fit, treatment-by-design model, and inconsistency factor.
The inconsistency plot is shown in Figure 5. As shown in Figure 5,
there was only one comparison for which direct and indirect esti-
mates were available. Forest plots ofmortality (networkmeta-anal-
ysis estimates and direct comparisons when available) are shown
in Figure 6. Both fixed-effect model and random-effects model
for other interventions compared with tacrolimus are provided in
Figure 6. As shown in the figure, the direct estimates and network
meta-analysis estimates of different models were similar except
for tacrolimus plus sirolimus versus tacrolimus. Tacrolimus plus
sirolimus causes more mortality at maximal follow-up compared
with tacrolimus in the direct comparison involving one trial and
fixed-effect model of network meta-analysis, but not in the ran-
dom-effects model of network meta-analysis. Several other com-
parisons in which there was evidence of difference in fixed-effect
model showed no evidence of difference based on random-effects
model. We used the more conservative random-effects model to
arrive at conclusions. The pairwise meta-analysis estimates of the
random-effects model are shown in Figure 7. As shown in this
figure, there was no evidence of difference in any of the pairwise
comparisons in network meta-analysis, although direct compar-
isons of single trials showed that tacrolimus plus sirolimus had
higher mortality than tacrolimus (hazard ratio (HR) 2.76, 95%
credible interval (CrI) 1.30 to 6.69) (1 trial; 222 participants),
and tacrolimus plus glucocorticosteroids had lower mortality than
cyclosporine A plus azathioprine plus glucocorticosteroids (HR
0.06, 95% CrI 0.00 to 0.91) (1 trial; 39 participants). The surface
area under the curve for each intervention being best, second best,
third best, and so on, and the ranking probabilities of each inter-
vention being best, second best, third best, and so on, are shown
in Figure 8. None of the interventions seems to be clearly better
than any of the others.
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Figure 5. IF (Inconsistency Factor) plots of outcomes in which there were comparisons for which direct and
indirect estimates were available (i.e. mortality at maximal follow-up and graft rejection requiring treatment).
There was no evidence of inconsistency in these outcomes, as the confidence intervals of the inconsistency
factor overlapped one.
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Figure 6. Forest plot of mortality at maximal follow-up (network meta-analysis estimates and direct
comparisons when available). Both fixed-effect model and random-effects model for other Interventions
compared to tacrolimus are provided. The direct estimates and network meta-analysis estimates are similar
except for tacrolimus plus sirolimus versus tacrolimus. Tacrolimus plus sirolimus causes more mortality at
maximal follow-up in the direct comparison involving one trial and fixed-effect model of network meta-analysis
but not in the random-effects model of network meta-analysis. We used the more conservative random-
effects model to arrive at conclusions.Abbreviations: Tac = tacrolimus; Cy = cyclosporine A; Myc =
mycophenolate; Aza = azathioprine; Sir = sirolimus; Ever = everolimus; Std = glucocorticosteroids; ˙ = plus
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Figure 7. The table provides the effect estimate (hazard ratio) of each pairwise comparison for mortality at
maximal follow-up. The top half of the table indicates the effect estimates from the direct comparisons. The
bottom half of the table indicates the effect estimates from the network meta-analysis. For network meta-
analysis, to identify the effect estimate of a comparison, say A versus B, look at the cell that occupies the row
corresponding to intervention A and the column corresponding to intervention B for the direct effect
estimate. If that cell is empty (indicated by a ’-’), look at the row corresponding to intervention B and the
column corresponding to intervention A. Take the inverse of this number (i.e. 1/number) to arrive at the
treatment effect of A versus B. For direct comparisons, this is exactly the opposite; look at the cell that
occupies the column corresponding to intervention A and the row corresponding to intervention B for the
direct effect estimate. If that cell is empty, look at the column corresponding to intervention B and the row
corresponding to intervention A. Take the inverse of this number to arrive at the treatment effect of A versus
B. If the cell corresponding to B versus A is also missing in direct comparisons, this means that there was no
direct comparison.Treatment effects with evidence of difference are shown in italics. As presented, there is no
evidence of difference in any of the pairwise comparisons in the network meta-analysis, although direct
comparison showed that tacrolimus plus sirolimus had higher mortality than tacrolimus, and tacrolimus plus
glucocorticosteroids had lower mortality than cyclosporine A plus azathioprine plus glucocorticosteroids in
single trials.* = single trialAbbreviations: Tac = tacrolimus; Cy = cyclosporine A; Myc = mycophenolate; Aza =
azathioprine; Sir = sirolimus; Ever = everolimus; Std = glucocorticosteroids; ˙ = plus
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Figure 8. Mortality (maximal follow-up) A. The figure shows the surface area under the curve constructed
on the basis of the ranking probabilities.B. The figure shows the probability of each Intervention being best,
second best, third best, and so on. There was no evidence that one Intervention is clearly better than any of
the other Interventions.Legend: 1: tacrolimus; 2: cyclosporine A; 3: cyclosporine A plus azathioprine; 4:
cyclosporine A plus azathioprine plus glucocorticosteroids; 5: cyclosporine A plus mycophenolate plus
glucocorticosteroids; 6: cyclosporine A plus glucocorticosteroids; 7: everolimus; 8: tacrolimus plus
azathioprine; 9: tacrolimus plus everolimus; 10: tacrolimus plus mycophenolate plus glucocorticosteroids; 11:
tacrolimus plus sirolimus; 12: tacrolimus plus glucocorticosteroids.
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Graft loss at maximal follow-up
The network meta-analysis of graft loss at maximal follow-up in-
cluded a total of 15 trials (2961 participants) (Fung 1991; Stegall
1997; Zervos 1998; Jain 2001; Loinaz 2001; Chen 2002;O’Grady
2002; Greig 2003; Jonas 2005; Shenoy 2008; Boudjema 2011;
Cholongitas 2011; De Simone 2012; Asrani 2014; Manousou
2014). The between-study standard deviation (τ ) was 0.6253 (τ 2
= 0.3910; lies within the 95% range for semi-objective outcomes
in pharmacological comparisons) (Turner 2012). We could not
estimate the I2. There were no direct and indirect estimates for
the same comparison, and so we did not assess inconsistency. For-
est plots of graft loss (network meta-analysis estimates and direct
comparisons when available) are shown in Figure 9. Both fixed-
effect model and random-effects model for other interventions
compared to tacrolimus are provided in Figure 9. As shown in the
figure, the direct estimates and network meta-analysis estimates of
different models were similar except for tacrolimus plus sirolimus
versus tacrolimus. Tacrolimus plus sirolimus causes more graft loss
at maximal follow-up than tacrolimus in the direct comparison
(HR 2.34, 95% CrI 1.28 to 4.61) (1 trial; 222 participants) and
fixed-effect model of network meta-analysis but not in the ran-
dom-effectsmodel of networkmeta-analysis. As in the case ofmor-
tality at maximal follow-up, several other comparisons in which
there was evidence of difference in fixed-effectmodel did not show
any evidence of difference based on random-effects model. We
used the more conservative random-effects model to arrive at con-
clusions. The pairwise meta-analysis estimates of the random-ef-
fects model are shown in Figure 10. As shown in Figure 10, there
was no evidence of difference in any of the pairwise comparisons
in the network meta-analysis. The surface area under the curve
for each intervention being best, second best, third best, and so
on and the ranking probabilities of each intervention being best,
second best, third best, and so on are shown in Figure 11. None of
the interventions seems to be clearly better than any of the others.
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Figure 9. Forest plot of graft loss at maximal follow-up (network meta-analysis estimates and direct
comparisons when available). Both fixed-effect model and random-effects model for other Interventions
compared to tacrolimus are provided. The direct estimates and network meta-analysis estimates are similar
except for tacrolimus plus sirolimus versus tacrolimus. Tacrolimus plus sirolimus causes more graft loss at
maximal follow-up in the direct comparison involving one trial and fixed-effect model of network meta-analysis
but not in the random-effects model of network meta-analysis. We used the more conservative random-
effects model to arrive at conclusions.Abbreviations: Tac = tacrolimus; Cy = cyclosporine A; Myc =
mycophenolate; Aza = azathioprine; Sir = sirolimus; Ever = everolimus; Std = glucocorticosteroids; ˙ = plus
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Figure 10. The table provides the effect estimate (hazard ratio) of each pairwise comparison for graft loss
at maximal follow-up. The top half of the table indicates the effect estimates from the direct comparisons. The
bottom half of the table indicates the effect estimates from the network meta-analysis. For network meta-
analysis, to identify the effect estimate of a comparison, say A versus B, look at the cell that occupies the row
corresponding to intervention A and the column corresponding to intervention B for the direct effect
estimate. If that cell is empty (indicated by a ’-’), look at the row corresponding to intervention B and the
column corresponding to intervention A. Take the inverse of this number (i.e. 1/number) to arrive at the
treatment effect of A versus B. For direct comparisons, this is exactly the opposite; look at the cell that
occupies the column corresponding to intervention A and the row corresponding to intervention B for the
direct effect estimate. If that cell is empty, look at the column corresponding to intervention B and the row
corresponding to intervention A. Take the inverse of this number to arrive at the treatment effect of A versus
B. If the cell corresponding to B versus A is also missing in direct comparisons, this means that there was no
direct comparison.Treatment effects with evidence of difference are shown in italics. As presented, there was
no evidence of difference in any of the pairwise comparisons in the network meta-analysis, although tacrolimus
plus sirolimus appears to increase graft loss at maximal follow-up compared to tacrolimus.* single
trialAbbreviations: Tac = tacrolimus; Cy = cyclosporine A; Myc = mycophenolate; Aza = azathioprine; Sir =
sirolimus; Ever = everolimus; Std = glucocorticosteroids; ˙ = plus
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Figure 11. Graft loss (maximal follow-up) A. The figure shows the surface area under the curve constructed
on the basis of the ranking probabilities.B. The figure shows the probability of each Intervention being best,
second best, third best, and so on. There was no evidence that one intervention is clearly better than any of
the other interventions.Legend: 1: tacrolimus; 2: cyclosporine A; 3: cyclosporine A plus azathioprine; 4:
everolimus; 5: tacrolimus plus azathioprine; 6: tacrolimus plus everolimus; 7: tacrolimus plus mycophenolate
plus glucocorticosteroids; 8: tacrolimus plus sirolimus; 9: tacrolimus plus glucocorticosteroids.
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Adverse events
Serious adverse events (proportion)
One trial (719 participants) reported on proportion of people with
serious adverse events (De Simone 2012). There was no evidence
that any of the pair-wise comparisons affected the proportion of
people with serious adverse events:
• everolimus versus tacrolimus: odds ratio (OR) 1.40 (95%
CrI 0.98 to 2.03);
• everolimus plus tacrolimus versus tacrolimus: OR 1.21
(95% CrI 0.85 to 1.75);
• everolimus plus tacrolimus versus everolimus: OR 0.86
(95% CrI 0.60 to 1.24).
Serious adverse events (number)
None of the trials reported the number of serious adverse events.
Any adverse events (proportion)
A total of two trials including 940 participants reported propor-
tion of people with adverse events and were included in the net-
workmeta-analysis (De Simone 2012; Asrani 2014). The between-
study standard deviation was so small that it was very close to
the prior value (average standard deviation of the uniform dis-
tribution of 2.5). We could not estimate the I2. There were no
direct and indirect estimates for the same comparison, and so we
did not assess inconsistency. Forest plots of adverse events (pro-
portion) (network meta-analysis estimates and direct comparisons
when available) are shown in Figure 12. Both fixed-effect model
and random-effects model for other interventions compared to
tacrolimus are provided in Figure 12. As shown in the figure, the
direct estimates and network meta-analysis estimates of different
models were similar. There was no evidence of difference between
any of the interventions (Figure 13), despite the surface area un-
der the curve for each intervention being best, second best, third
best, and so on and the ranking probabilities of each intervention
being best, second best, third best showing that tacrolimus plus
sirolimus may be the worst intervention in terms of adverse events
(proportion) (Figure 14).
Figure 12. Forest plot of adverse events (proportion) (network meta-analysis estimates and direct
comparisons when available). Both fixed-effect model and random-effects model for other interventions
compared with tacrolimus are provided. The direct estimates and network meta-analysis estimates are
similar. As there was only trial for each comparison, the random-effects model for the direct comparisons is
not provided. There was no evidence of difference between any of the comparisons.Abbreviations: Tac =
tacrolimus; Ever = everolimus; Sir = sirolimus
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Figure 13. The table provides the effect estimate (odds ratio) of each pairwise comparison for adverse
events (proportion) corresponding to intervention B. The top half of the table indicates the effect estimates
from the direct comparisons. The bottom half of the table indicates the effect estimates from the network
meta-analysis. For network meta-analysis, to identify the effect estimate of a comparison, say A versus B, look
at the cell that occupies the row corresponding to intervention A and the column corresponding to
intervention B for the direct effect estimate. If that cell is empty (indicated by a ’-’), look at the row
corresponding to intervention B and the column corresponding to intervention A. Take the inverse of this
number (i.e. 1/number) to arrive at the treatment effect of A versus B. For direct comparisons, this is exactly
the opposite; look at the cell that occupies the column corresponding to intervention A and the row
corresponding to intervention B for the direct effect estimate. If that cell is empty, look at the column
corresponding to intervention B and the row corresponding to intervention A. Take the inverse of this number
to arrive at the treatment effect of A versus B. If the cell corresponding to B versus A is also missing in direct
comparisons, this means that there was no direct comparison.Treatment effects with evidence of difference
are shown in italics. As presented, there was no evidence of difference in any of the pairwise comparisons.*
single trialAbbreviations: Tac = tacrolimus; Ever = everolimus; Sir = sirolimus
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Figure 14. Adverse events (proportion)A. The figure shows the surface area under the curve constructed
on the basis of the ranking probabilities.B. The figure shows the probability of each Intervention being best,
second best, third best, and so on. Although the figure shows that tacrolimus plus sirolimus was the worst
intervention in terms of adverse events (proportion), there was no evidence of differences in the odds ratios
between the different interventions.Legend: 1: tacrolimus; 2: everolimus; 3: tacrolimus plus everolimus; 4:
tacrolimus plus sirolimus.
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Any adverse events (number)
The network meta-analysis included a total of 12 trials (1748 par-
ticipants) that reported the number of adverse events (Fung 1991;
Stegall 1997; Belli 1998; Zervos 1998; Loinaz 2001; O’Grady
2002; Greig 2003; Pageaux 2004; Shenoy 2008; Masetti 2010;
Boudjema 2011; Pelletier 2013). The between-study standard de-
viationwas so small that it was very close to the prior value (average
standard deviation of the uniform distribution of 2.5). We could
not estimate the I2. There were no direct and indirect estimates
for the same comparison, and so we did not assess inconsistency.
Figure 15 shows forest plots of adverse events (numbers) (network
meta-analysis estimates and direct comparisons when available).
Both fixed-effect model and random-effects model for other in-
terventions compared to tacrolimus are provided in Figure 15. As
shown in the figure, the direct estimates and network meta-anal-
ysis estimates of different models were similar. We have reported
the fixed-effect model. The number of adverse events appears to
be lower in the cyclosporine A group than in the tacrolimus group.
Figure 16 shows the effect estimates of each pairwise comparison
from network meta-analysis and direct comparisons. As shown
in Figure 16, cyclosporine A appears to be associated with fewer
adverse events than tacrolimus and cyclosporine A plus gluco-
corticosteroids (based on both network meta-analysis and direct
comparisons), and fewer adverse events than tacrolimus plus my-
cophenolate and tacrolimus plus mycophenolate plus glucocor-
ticosteroids groups based on network meta-analysis. Tacrolimus
plus mycophenolate also appears to be associated with more ad-
verse events than everolimus based on network meta-analysis. The
surface area under the curve for each intervention being best, sec-
ond best, third best, and so on and the ranking probabilities of
each intervention being best, second best, third best show that
tacrolimus plus mycophenolate may be the worst intervention in
terms of number of adverse events (Figure 17). Cyclosporine A,
which has a high probability of being in the top-two ranks, was
associated with fewer adverse events than most of the other inter-
ventions except everolimus in the pairwise comparisons, as men-
tioned above.
Figure 15. Forest plot of adverse events (number) (network meta-analysis estimates and direct
comparisons when available). Both fixed-effect model and random-effects model for other interventions
compared to tacrolimus are provided. The direct estimates and network meta-analysis estimates are similar.
The number of adverse events appears to be higher for cyclosporine A than for tacrolimus. There was no
evidence of difference in the remaining comparisons with tacrolimus.Abbreviations: Cy = cyclosporine A; Tac =
tacrolimus; Ever = everolimus; Myc = mycophenolate; Sir = sirolimus; Std = glucocorticosteroids
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Figure 16. The table provides the effect estimate (rate ratio) of each pairwise comparison for adverse
events (number) corresponding to intervention B. The top half of the table indicates the effect estimates from
the direct comparisons. The bottom half of the table indicates the effect estimates from the network meta-
analysis. For network meta-analysis, to identify the effect estimate of a comparison, say A versus B, look at the
cell that occupies the row corresponding to intervention A and the column corresponding to intervention B for
the direct effect estimate. If that cell is empty (indicated by a ’-’), look at the row corresponding to intervention
B and the column corresponding to intervention A. Take the inverse of this number (i.e. 1/number) to arrive at
the treatment effect of A versus B. For direct comparisons, this is exactly the opposite; look at the cell that
occupies the column corresponding to intervention A and the row corresponding to intervention B for the
direct effect estimate. If that cell is empty, look at the column corresponding to intervention B and the row
corresponding to intervention A. Take the inverse of this number to arrive at the treatment effect of A versus
B. If the cell corresponding to B versus A is also missing in direct comparisons, this means that there was no
direct comparison.Treatment effects with evidence of difference are shown in italics. As presented,
cyclosporine A appears to be associated with fewer adverse events than tacrolimus and cyclosporine A plus
glucocorticosteroids (based on both network meta-analysis and direct comparisons), and fewer adverse events
than tacrolimus plus mycophenolate and tacrolimus plus mycophenolate plus glucocorticosteroids based on
network meta-analysis. Tacrolimus plus mycophenolate also appears to be associated with more adverse
events than everolimus based on network meta-analysis.* single trialAbbreviations: Cy = cyclosporine A; Tac =
tacrolimus; Ever = everolimus; Myc = mycophenolate; Sir = sirolimus; Std = glucocorticosteroids
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Figure 17. Adverse events (number)A. The figure shows the surface area under the curve constructed on
the basis of the ranking probabilities.B. The figure shows the probability of each Intervention being best,
second best, third best, and so on. Although the figure shows that tacrolimus plus mycophenolate appears to
be the worst intervention in terms of number of adverse events, the pairwise comparisons show that there was
no evidence of difference between tacrolimus plus mycophenolate and other comparisons except everolimus.
Cylosporine A, which has a high probability of being in the top two ranks, was associated with fewer adverse
events than other interventions with the exception of everolimus in the pairwise comparisons.Legend: 1:
tacrolimus; 2: cyclosporine A; 3: cyclosporine A plus glucocorticosteroids; 4: everolimus; 5: tacrolimus plus
mycophenolate; 5: tacrolimus plus mycophenolate plus glucocorticosteroids.
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Renal impairment
The network meta-analysis included a total of eight trials (2233
participants) for renal impairment (Fung 1991; Porayko1994; Jain
2001; O’Grady 2002; Greig 2003; Boudjema 2011; De Simone
2012; Pelletier 2013). The between-study standard deviation (τ )
was 1.273 (τ 2 = 1.6205; lies outside the 95% range for semi-ob-
jective outcomes in pharmacological comparisons) (Turner 2012).
We could not estimate the I2. There were no direct and indirect
estimates for the same comparison, and so we did not assess incon-
sistency. Figure 18 shows forest plots of renal impairment (network
meta-analysis estimates and direct comparisons when available).
Both fixed-effect model and random-effects model for other in-
terventions compared to tacrolimus are provided in Figure 18. As
shown in the figure, the direct estimates and network meta-analy-
sis estimates of different models were similar except for tacrolimus
plus mycophenolate plus glucocorticosteroids versus tacrolimus.
Tacrolimus plus mycophenolate plus glucocorticosteroids causes
less renal impairment comparedwith tacrolimus in the direct com-
parison involving one trial andfixed-effectmodel of networkmeta-
analysis, but not in the random-effects model of network meta-
analysis. We used the more conservative random-effects model to
arrive at conclusions. Figure 19 shows the pairwise meta-analysis
estimates of the random-effects model. As shown in Figure 19,
there is no evidence of difference in any of the pairwise com-
parisons in network meta-analysis, although direct comparison
of a single trial showed tacrolimus plus mycophenolate plus glu-
cocorticosteroids to have less renal impairment compared with
tacrolimus. The surface area under the curve for each interven-
tion being best, second best, third best, and so on and the ranking
probabilities of each intervention being best, second best, third
best, and so on are shown in Figure 20. None of the interventions
seems to be clearly better than any of the others.
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Figure 18. Forest plot of renal impairment (network meta-analysis estimates and direct comparisons when
available). Both fixed-effect model and random-effects model for other interventions compared to tacrolimus
are provided. The direct estimates and network meta-analysis estimates are similar except for tacrolimus plus
mycophenolate plus glucocorticosteroids versus tacrolimus. Tacrolimus plus mycophenolate plus
glucocorticosteroids causes less renal impairment in the direct comparison involving one trial and fixed-effect
model of network meta-analysis but not in the random-effects model of network meta-analysis. We used the
more conservative random-effects model to arrive at conclusions.Abbreviations: Tac = tacrolimus; Cy =
cyclosporine A; Myc = mycophenolate; Aza = azathioprine; Ever = everolimus; Std = glucocorticosteroids; ˙ =
plus
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Figure 19. The table provides the effect estimate (hazard ratio) of each pairwise comparison for renal
impairment. The top half of the table indicates the effect estimates from the direct comparisons. The bottom
half of the table indicates the effect estimates from the network meta-analysis. For network meta-analysis, to
identify the effect estimate of a comparison, say A versus B, look at the cell that occupies the row
corresponding to intervention A and the column corresponding to intervention B for the direct effect
estimate. If that cell is empty (indicated by a ’-’), look at the row corresponding to intervention B and the
column corresponding to intervention A. Take the inverse of this number (i.e. 1/number) to arrive at the
treatment effect of A versus B. For direct comparisons, this is exactly the opposite; look at the cell that
occupies the column corresponding to intervention A and the row corresponding to intervention B for the
direct effect estimate. If that cell is empty, look at the column corresponding to intervention B and the row
corresponding to intervention A. Take the inverse of this number to arrive at the treatment effect of A versus
B. If the cell corresponding to B versus A is also missing in direct comparisons, this means that there was no
direct comparison.Treatment effects with evidence of difference are shown in italics. As presented, there was
no evidence of difference in any of the pairwise comparisons in the network meta-analysis, although tacrolimus
plus mycophenolate plus glucocorticosteroids was associated with less renal impairment than tacrolimus in a
single trial.* single trialAbbreviations: Tac = tacrolimus; Cy = cyclosporine A; Myc = mycophenolate; Aza =
azathioprine; Ever = everolimus; Std = glucocorticosteroids; ˙ = plus
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Figure 20. Renal impairmentA. The figure shows the surface area under the curve constructed on the basis
of the ranking probabilities.B. The figure shows the probability of each Intervention being best, second best,
third best, and so on. There was no evidence that one intervention is clearly better than any of the other
interventions.Legend: 1: tacrolimus; 2: cyclosporine A; 3: cyclosporine A plus azathioprine plus
glucocorticosteroids; 4: everolimus; 5: tacrolimus plus everolimus; 6: tacrolimus plus mycophenolate; 7:
tacrolimus plus mycophenolate plus glucocorticosteroids; 8: tacrolimus plus glucocorticosteroids.
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Chronic kidney disease
Only one trial (100 participants) reported chronic kidney dis-
ease (Pelletier 2013). There was no evidence of difference be-
tween tacrolimus plus mycophenolate plus glucocorticosteroids
and tacrolimus plus mycophenolate (OR 0.38, 95% CrI 0.11 to
1.17).
Health-related quality of life
None of the trials reported health-related quality of life at any time
point.
Retransplantation
The network meta-analysis included a total of 13 trials (1994
participants) for retransplantation (Fung 1991; Porayko 1994;
Zervos 1998; Jain 2001; Chen 2002; O’Grady 2002; Greig 2003;
Jonas 2005; Shenoy 2008; Boudjema 2011; Cholongitas 2011;
Pelletier 2013; Manousou 2014). The between-study standard
deviation (τ ) was 0.7429 (τ 2 = 0.5519; lies within the 95%
range for semi-objective outcomes in pharmacological compar-
isons) (Turner 2012). We could not estimate the I2. There were
no direct and indirect estimates for the same comparison, and
so we did not assess inconsistency. Forest plots of retransplan-
tation (network meta-analysis estimates and direct comparisons
when available) are shown in Figure 21. Both fixed-effect model
and random-effects model for other interventions compared with
tacrolimus are provided in Figure 21. As shown in the figure, the
direct estimates and network meta-analysis estimates of different
models were similar. Cyclosporine A resulted in higher incidence
of retransplantation compared with tacrolimus. As there were dif-
ferences in the effect estimates in other comparisons, we used the
more conservative random-effects model to arrive at conclusions.
The pair-wisemeta-analysis estimates of the random-effectsmodel
are shown in Figure 22. As shown in Figure 21, cyclosporine A had
a higher incidence of retransplantation compared with tacrolimus
(HR 3.08, 95% CrI 1.13 to 9.90), and tacrolimus plus mycophe-
nolate plus glucocorticosteroids had a lower incidence of retrans-
plantation compared with tacrolimus plus mycophenolate (HR
0.03, 95% CrI 0.00 to 0.90). The surface area under the curve
for each intervention being best, second best, third best, and so
on and the ranking probabilities of each intervention being best,
second best, third best, and so on are shown in Figure 23. None of
the interventions seems to be clearly better than any of the others.
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Figure 21. Forest plot of retransplantation (network meta-analysis estimates and direct comparisons when
available). Both fixed-effect model and random-effects model for other interventions compared to tacrolimus
are provided. The direct estimates and network meta-analysis estimates are similar, although the random-
effects model was more conservative. Cyclosporine A resulted in higher incidence of retransplantation than
tacrolimus.Abbreviations: Tac = tacrolimus; Cy = cyclosporine A; Myc = mycophenolate; Aza = azathioprine;
Std = glucocorticosteroids; ˙ = plus
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Figure 22. The table provides the effect estimate (hazard ratio) of each pairwise comparison for
retransplantation. The top half of the table indicates the effect estimates from the direct comparisons. The
bottom half of the table indicates the effect estimates from the network meta-analysis. For network meta-
analysis, to identify the effect estimate of a comparison, say A versus B, look at the cell that occupies the row
corresponding to intervention A and the column corresponding to intervention B for the direct effect
estimate. If that cell is empty (indicated by a ’-’), look at the row corresponding to intervention B and the
column corresponding to intervention A. Take the inverse of this number (i.e. 1/number) to arrive at the
treatment effect of A versus B. For direct comparisons, this is exactly the opposite; look at the cell that
occupies the column corresponding to intervention A and the row corresponding to intervention B for the
direct effect estimate. If that cell is empty, look at the column corresponding to intervention B and the row
corresponding to intervention A. Take the inverse of this number to arrive at the treatment effect of A versus
B. If the cell corresponding to B versus A is also missing in direct comparisons, this means that there was no
direct comparison.Treatment effects with evidence of difference are shown in italics. As presented,
cyclosporine A is associated with a higher incidence of retransplantation than tacrolimus, and tacrolimus plus
mycophenolate plus glucocorticosteroids showed a lower incidence of retransplantation than tacrolimus plus
mycophenolate.* single trialAbbreviations: Tac = tacrolimus; Cy = cyclosporine A; Myc = mycophenolate; Aza
= azathioprine; Std = glucocorticosteroids; ˙ = plus
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Figure 23. RetransplantationA. The figure shows the surface area under the curve constructed on the basis
of the ranking probabilities.B. The figure shows the probability of each Intervention being best, second best,
third best, and so on. There was no evidence that one intervention is clearly better than any of the other
interventions.Legend: 1: tacrolimus; 2: cyclosporine A; 3: cyclosporine A plus azathioprine; 4: cyclosporine A
plus azathioprine plus glucocorticosteroids; 5: tacrolimus plus azathioprine; 6: tacrolimus plus mycophenolate;
7: tacrolimus plus mycophenolate plus glucocorticosteroids; 8: tacrolimus plus glucocorticosteroids
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Graft rejections
Graft rejections (any)
Network meta-analysis of graft rejections (any) included a to-
tal of 16 trials (2726 participants) (Fung 1991; Porayko 1994;
Fisher 1998; Zervos 1998; Loinaz 2001; O’Grady 2002; Greig
2003; Martin 2004; Pageaux 2004; Jonas 2005; Shenoy 2008;
Boudjema 2011; Cholongitas 2011; De Simone 2012; Pelletier
2013; Manousou 2014). The between-study standard deviation
(τ ) was 0.5755 (τ 2 = 0.3312; lies within the 95% range for sub-
jective outcomes in pharmacological comparisons) (Turner 2012).
We could not estimate the I2. There were no direct and indi-
rect estimates for the same comparison, and so we did not as-
sess inconsistency. Forest plots of graft rejections (any) (network
meta-analysis estimates and direct comparisons when available)
are shown in Figure 24. Both fixed-effect model and random-ef-
fects model for other interventions compared with tacrolimus are
provided in Figure 24. As shown in the figure, the direct estimates
(fixed-effect model) and fixed-effect network meta-analysis esti-
mates were similar and demonstrated fewer graft rejections (any)
in tacrolimus plus everolimus and tacrolimus plus mycopheno-
late plus glucocorticosteroids than tacrolimus, while there were
more graft rejections (any) with cyclosporine A and everolimus
compared with tacrolimus. However, the random-effects model
did not demonstrate any evidence of difference in graft rejections
(any) for any comparison.We used themore conservative random-
effects model to arrive at conclusions. The pairwise meta-analysis
estimates of the random-effects model are shown in Figure 25. As
shown in Figure 25, there was no evidence of difference in any
of the pairwise comparisons in network meta-analysis, although
direct comparisons involving single trials showed fewer graft rejec-
tions (any) in the tacrolimus plus everolimus and tacrolimus plus
mycophenolate plus glucocorticosteroids groups compared with
the tacrolimus group, while cyclosporine A and everolimus had
more graft rejections (any) compared with tacrolimus in single
trials. Tacrolimus plus everolimus also had fewer graft rejections
(any) compared with everolimus based on evidence from a single
trial. The surface area under the curve for each intervention being
best, second best, third best, and so on and the ranking probabil-
ities of each intervention being best, second best, third best, and
so on are shown in Figure 26. None of the interventions seems to
be clearly better than any of the others.
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Figure 24. Forest plot of graft rejections (any) (network meta-analysis estimates and direct comparisons
when available). Both fixed-effect model and random-effects model for other interventions compared to
tacrolimus are provided. The direct estimates and fixed-effect network meta-analysis estimates are similar and
demonstrate fewer graft rejections (any) for tacrolimus plus everolimus and tacrolimus plus mycophenolate
plus glucocorticosteroids than for tacrolimus, while cyclosporine A and everolimus were associated with more
graft rejections (any) than tacrolimus. However, the random-effects model did not demonstrate any evidence
of difference in graft rejections (any) for any comparison. We used the more conservative random-effects
model to arrive at conclusions.Abbreviations: Tac = tacrolimus; Cy = cyclosporine A; Myc = mycophenolate;
Aza = azathioprine; Ever = everolimus; Std = glucocorticosteroids; ˙ = plus
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Figure 25. The table provides the effect estimate (hazard ratio) of each pairwise comparison for graft
rejections (any). The top half of the table indicates the effect estimates from the direct comparisons. The
bottom half of the table indicates the effect estimates from the network meta-analysis. For network meta-
analysis, to identify the effect estimate of a comparison, say A versus B, look at the cell that occupies the row
corresponding to intervention A and the column corresponding to intervention B for the direct effect
estimate. If that cell is empty (indicated by a ’-’), look at the row corresponding to intervention B and the
column corresponding to intervention A. Take the inverse of this number (i.e. 1/number) to arrive at the
treatment effect of A versus B. For direct comparisons, this is exactly the opposite; look at the cell that
occupies the column corresponding to intervention A and the row corresponding to intervention B for the
direct effect estimate. If that cell is empty, look at the column corresponding to intervention B and the row
corresponding to intervention A. Take the inverse of this number to arrive at the treatment effect of A versus
B. If the cell corresponding to B versus A is also missing in direct comparisons, this means that there was no
direct comparison.Treatment effects with evidence of difference are shown in italics. As presented, there was
no evidence of difference in any of the pairwise comparisons in the network meta-analysis, although direct
comparison showed fewer graft rejections (any) for tacrolimus plus everolimus and tacrolimus plus
mycophenolate plus glucocorticosteroids than for tacrolimus, while cyclosporine A and everolimus were
associated with more graft rejections (any) than tacrolimus in single trials. Tacrolimus plus everolimus also
showed fewer graft rejections (any) than everolimus based on evidence from a single trial.* = single
trialAbbreviations: Tac = tacrolimus; Cy = cyclosporine A; Myc = mycophenolate; Aza = azathioprine; Ever =
everolimus; Std = glucocorticosteroids; ˙ = plus
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Figure 26. Graft rejections (any)A. The figure shows the surface area under the curve constructed on the
basis of the ranking probabilities.B. The figure shows the probability of each Intervention being best, second
best, third best, and so on. There was no evidence that one intervention is clearly better than any of the other
interventions.Legend: 1: tacrolimus; 2: cyclosporine A; 3: cyclosporine A plus azathioprine; 4: cyclosporine A
plus azathioprine plus corticosteroids; 5: cyclosporine A plus mycophenolate; 6: cyclosporine A plus
glucocorticosteroids; 7: everolimus; 8: tacrolimus plus azathioprine; 9: tacrolimus plus everolimus; 10:
tacrolimus plus mycophenolate; 11: tacrolimus plus mycophenolate plus glucocorticosteroids; 12: tacrolimus
plus glucocorticosteroids.
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Graft rejections requiring treatment
Network meta-analysis included a total of five trials (1025 partic-
ipants) for graft rejections requiring treatment (Stegall 1997; Belli
1998; Masetti 2010; Cholongitas 2011; De Simone 2012). In the
network meta-analysis, the between-study standard deviation (τ )
was 0.9127 (τ 2 = 0.8330; lies within the 95% range for subjective
outcomes in pharmacological comparisons) (Turner 2012). We
could not estimate the I2. There was no evidence of inconsistency
as evidenced by the model fit, treatment-by-design model, and
inconsistency factor. The inconsistency plot is shown in Figure
5. However, as shown in Figure 5, there was only one compari-
son for which direct and indirect estimates were available. Forest
plots of graft rejections requiring treatment (network meta-anal-
ysis estimates and direct comparisons when available) are shown
in Figure 27. Both fixed-effect model and random-effects model
for other interventions compared with tacrolimus are provided
in Figure 27. As shown in the figure, the direct estimates and
network meta-analysis estimates of different models were similar
except for everolimus versus tacrolimus. Everolimus causes more
graft rejections requiring treatment compared with tacrolimus in
the direct comparison involving one trial and fixed-effect model
of network meta-analysis, but not in the random-effects model of
network meta-analysis. One other comparison in which there was
evidence of difference in fixed-effect model did not show evidence
of difference based on random-effects model. We used the more
conservative random-effects model to arrive at conclusions. The
pairwise meta-analysis estimates of the random-effects model are
shown in Figure 28. As shown in Figure 28, there was no evi-
dence of difference in any of the pairwise comparisons in network
meta-analysis, although direct comparisons involving single trials
showed everolimus to have a higher incidence of graft rejections re-
quiring treatment compared with tacrolimus and tacrolimus plus
everolimus. The surface area under the curve for each interven-
tion being best, second best, third best, and so on and the ranking
probabilities of each intervention being best, second best, third
best, and so on are shown in Figure 29. None of the interventions
seems to be clearly better than any of the others.
Figure 27. Forest plot of graft rejections requiring treatment (network meta-analysis estimates and direct
comparisons when available). Both fixed-effect model and random-effects model for other interventions
compared to tacrolimus are provided. The direct estimates and network meta-analysis estimates are similar
except for everolimus versus tacrolimus. Everolimus causes more graft rejections than tacrolimus in the direct
comparison involving one trial and fixed-effect model of network meta-analysis but not in the random-effects
model of network meta-analysis. We used the more conservative random-effects model to arrive at
conclusions.Abbreviations: Tac = tacrolimus; Cy = cyclosporine A; Myc = mycophenolate; Aza = azathioprine;
Sir = sirolimus; Ever = everolimus; Std = glucocorticosteroids; ˙ = plus
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Figure 28. The table provides the effect estimate (hazard ratio) of each pairwise comparison for graft
rejection requiring treatment. The top half of the table indicates the effect estimates from the direct
comparisons. The bottom half of the table indicates the effect estimates from the network meta-analysis. For
network meta-analysis, to identify the effect estimate of a comparison, say A versus B, look at the cell that
occupies the row corresponding to intervention A and the column corresponding to intervention B for the
direct effect estimate. If that cell is empty (indicated by a ’-’), look at the row corresponding to intervention B
and the column corresponding to intervention A. Take the inverse of this number (i.e. 1/number) to arrive at
the treatment effect of A versus B. For direct comparisons, this is exactly the opposite; look at the cell that
occupies the column corresponding to intervention A and the row corresponding to intervention B for the
direct effect estimate. If that cell is empty, look at the column corresponding to intervention B and the row
corresponding to intervention A. Take the inverse of this number to arrive at the treatment effect of A versus
B. If the cell corresponding to B versus A is also missing in direct comparisons, this means that there was no
direct comparison.Treatment effects with evidence of difference are shown in italics. As presented, there was
no evidence of difference in any of the pairwise comparisons in the network meta-analysis, although direct
comparison showed that everolimus caused more graft rejections requiring treatment than tacrolimus and
tacrolimus plus everolimus in a single trial.* = single trialAbbreviations: Tac = tacrolimus; Cy = cyclosporine A;
Myc = mycophenolate; Aza = azathioprine; Sir = sirolimus; Ever = everolimus; Std = glucocorticosteroids; ˙ =
plus
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Figure 29. Graft rejections requiring treatmentA. The figure shows the surface area under the curve
constructed on the basis of the ranking probabilities.B. The figure shows the probability of each Intervention
being best, second best, third best, and so on. There was no evidence that one intervention is clearly better
than any of the other interventions.Legend: 1: tacrolimus; 2: cyclosporine A; 3: cyclosporine A plus
glucocorticosteroids; 4: everolimus; 5: tacrolimus plus everolimus.
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Costs
None of the trials reported on costs.
Subgroup analyses
Because of the nature of the data (most trials included only partic-
ipants undergoing primary transplantation; most trials included
participants with varied aetiology without separate outcome data
based on aetiology; and the absence of any one trial at low risk of
bias), we did not perform these subgroup analyses. We considered
tacrolimus and cyclosporine A as different interventions, therefore
we did not perform a subgroup analysis of the same class of drugs.
We performed a post hoc subgroup analysis of trials in which the
drug combination of the induction immunosuppression differed
from that of the maintenance immunosuppression (i.e. additional
drug was used for induction) compared to trials in which the drug
combinationof the induction immunosuppressionwas the same as
that of the maintenance immunosuppression (no additional drug
was used for induction). The credible intervals of the interaction
term were extremely wide and overlapped zero for all comparisons
other than adverse events (number). The interaction term for the
meta-regression of adverse events (number) was 0.80 (95% CrI
0.37 to 1.70). However, it should be noted that in only one of the
trials in this comparison did participants receive the same drug
combination as the induction and maintenance immunosuppres-
sion (Pelletier 2013). A subgroup analysis did not alter the inter-
pretation of the results.
Sensitivity analysis
We did not perform a sensitivity analysis of imputing informa-
tion based on different scenarios because of the paucity of data
to carry out these analyses (i.e. the postrandomisation dropouts
when described were few, and the trial authors did not report the
participant flow adequately to perform these sensitivity analyses).
We did not impute standard deviation (as none of the trials re-
ported health-related quality of life or costs), therefore we did not
perform a sensitivity analysis to assess the impact of imputing the
standard deviation.
Trial Sequential Analysis
Weperformed a Trial Sequential Analysis for mortality at maximal
follow-up for various comparisons. As shown in Figure 30 and
Figure 31, the cumulative Z-curves (blue lines) did not cross any
of the trial sequential monitoring boundaries (red lines) for any
of the comparisons, and neither did they cross the conventional
alpha boundary of 2.5% (green lines), suggesting a high risk of
random error.
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Figure 30. Trial Sequential Analysis of mortality at maximal follow-up for cyclosporine A versus tacrolimus.
We used an alpha error of 2.5%, power of 90% (beta error of 10%), a relative risk reduction (RRR) of 20%
(upper figure) and that observed in trials (12%) (lower figure), control group proportion (Pc) observed in the
trials (15.4% mortality), and I2 of 0% (upper figure) and that observed in the trials (I2 = 39%) (lower figure).
The accrued sample size (1176) is only a fraction of the information size (IS) (6528 trial participants) or
heterogeneity-adjusted information size (HIS) (31,317 trial participants). As shown in all of the comparisons,
the cumulative Z-curves (blue line) do not cross any of the trial sequential monitoring boundaries (red lines),
and neither do they cross the conventional alpha boundary of 2.5% (green line).
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Figure 31. Trial Sequential Analysis of mortality at maximal follow-up for cyclosporine A plus azathioprine
versus tacrolimu. We used an alpha error of 2.5%, power of 90% (beta error of 10%), a relative risk reduction
(RRR) of 20% (upper figure) and that observed in trials (12%) (lower figure), control group proportion (Pc)
observed in the trials (15.4% mortality), and I2 of 0% (heterogeneity observed in the trials). The accrued
sample size (202) is only a fraction of the information size (IS) (6528 trial participants) or heterogeneity-
adjusted information size (HIS) (2242 trial participants). As shown in all of the comparisons, the cumulative Z-
curves (blue line) do not cross any of the trial sequential monitoring boundaries (red lines), and neither do
they cross the conventional alpha boundary of 2.5% (green line).
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Quality of evidence
The overall quality of the evidence was low or very low for all
comparisons due to the high risk of bias in the trials (downgraded
by one level); heterogeneity for indirect comparisons, as there were
differences in the effect estimates obtained by fixed-effect model
and random-effectsmodel (downgraded by one level); indirectness
in all indirect comparisons because of sparse network made up of
trials of high risk of bias (downgraded one level); small sample size
for direct comparisons (downgraded by one level); and impreci-
sion for all comparisons in which the credible intervals overlapped
a clinically significant increase or reduction and clinically insignif-
icant increase or reduction (20% relative risk reduction was con-
sidered clinically significant) (downgraded by one level).
D I S C U S S I O N
Summary of main results
We included a total of 26 trials (3842 participants) in this review,
and 3693 participants from 23 trials were included in one or more
outcomes in this review assessing maintenance immunosuppres-
sion for adults undergoing liver transplantation. There was no ev-
idence of inconsistency in the two networks (mortality at maximal
follow-up and graft rejections requiring treatment) in which we
could assess this, and the effect estimates from direct comparisons
and network meta-analysis were reasonably similar.
The mortality (maximal follow-up) and graft loss (maximal fol-
low-up) were higher for tacrolimus plus sirolimus compared with
tacrolimus in a single trial including 222 participants based on
direct comparisons, however there was no evidence of difference
based on network meta-analysis results. It appears that adding
sirolimus to the standard immunosuppressive regimenworsens the
outcomes.Most trials did not report serious adverse events, despite
this being an important outcome for patients and healthcare fun-
ders. There were fewer adverse events with cyclosporine A com-
pared with tacrolimus in our network meta-analysis. As shown in
Figure 16, cyclosporine A appears to be associated with fewer ad-
verse events compared with most other interventions, but the im-
plications of this are unclear, as the impact of these adverse events
on the participant’s health-related quality of life was not reported.
There was no evidence of differences in renal impairment based
on network meta-analysis. Only one trial reported the number
of people with chronic kidney disease, despite this being one of
the major aspects determining the immunosuppressive regimen.
Most trials reported kidney function as the mean values in the
groups, which is not helpful in identifying whether people receiv-
ing a particular immunosuppressive regimen developed chronic
kidney disease more often. None of the trials reported health-re-
lated quality of life. This is an important clinical outcome that
should be reported in future trials.
Incidence of retransplantation was higher with cyclosporine A
compared with tacrolimus. Again, this is an important clinical
outcome, as it has huge implications for the patient and health-
care funders. A previous Cochrane systematic review that com-
pared tacrolimus and cyclosporine A (and accepted other mainte-
nance immunosuppressive agents as co-interventions) concluded
that tacrolimus was better than cyclosporine A in terms of patient
survival (Haddad 2006). It should also be noted that most re-
cent trials use tacrolimus monotherapy or tacrolimus-based ther-
apy as the control group, suggesting that tacrolimus is considered
the standard against which other immunosuppressive agents are
compared. We found no reliable evidence that any of the other
interventions are better than tacrolimus in our review. Future tri-
als on maintenance immunosuppression should therefore include
tacrolimus as the control group.
Overall completeness and applicability of
evidence
The trials included mainly people undergoing primary liver trans-
plantation for various aetiologies. The findings of this review are
therefore applicable to people undergoing primary liver transplan-
tation for any aetiology.We have only consideredmaintenance im-
munosuppression in adults. As graft rejections are more frequent
in the first few months after liver transplantation, higher doses
of the immunosuppression may be needed. However, additional
drugs (induction immunosuppression agents) are routinely used
with a view to decrease the number of graft rejections without re-
quiring a higher dose of maintenance immunosuppression. As we
evaluated only maintenance immunosuppression in this review,
our findings are applicable only to maintenance immunosuppres-
sion.
Quality of the evidence
The overall quality of the evidence was low or very low for all
outcomes. The main reasons for this were the trials at high risk of
bias, in particular the exclusion of participants from the analysis
after randomisation in some trials; small sample size; and impreci-
sion. Overall, there are serious concerns about whether the effect
estimates observed are the true effect estimates.
Potential biases in the review process
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We selected a range of databases to search without using any lan-
guage restrictions and conducted the network meta-analysis ac-
cording to NICE DSU guidance. In addition, we have presented
the results from fixed-effect model and random-effects model and
used the more conservative model. These are the strengths of the
review process.
We have excluded studies that compared variations in duration
or dose in the different interventions. Hence this review does not
provide information on whether one variation is better than an-
other. Another major limitation of this review was the paucity of
data. Few trials were included for each comparison; in many com-
parisons, only one trial was included. This makes it difficult to
assess whether the effect estimates are reproducible. This paucity
of data decreases the confidence in the results.
All of the network meta-analyses included only sparse data from
trials at high risk of bias. We were able to compare the direct and
indirect estimates for very few comparisons. This means that the
tests for inconsistency are underpowered. One of the underpin-
ning assumptions of a network meta-analysis is that the partici-
pants in the different comparisons are similar. As information on
the potential effect modifiers such as the reason for liver trans-
plantation was missing from some trials, we had to rely on our
judgement to assess the transitivity assumption. While there is no
reason to suggest that there is any difference in the type of peo-
ple included under different comparisons (Table 2), making firm
judgements based on such network meta-analysis having missing
information is inappropriate; for this reason we have also reported
the results of direct comparison for major outcomes, that is mor-
tality at maximal follow-up and graft loss at maximal follow-up,
in the conclusion.
We only included randomised clinical trials, which are known to
focus mostly on benefits and do not collect and report harms in
a detailed manner. According to our choice of studies (i.e. only
randomised clinical trials), it is possible that we missed a large
number of studies addressing reporting of harms. Accordingly, this
review is biased towards benefits ignoringharms.Wedid not search
for interventions and trials registered at regulatory authorities (e.g.
US Food and Drug Administration, European Medicines Agency,
etc.). We may have therefore overlooked trials, and as such trials
are usually unpublished, this lack of inclusion could make our
comparisons look more advantageous than they truly are. On the
other hand, inclusion of non-randomised studies in the network
meta-analysis can increase the differences in potential modifiers
and decrease the reliability of the findings of the network meta-
analysis.
Agreements and disagreements with other
studies or reviews
There has been no previous network meta-analysis or system-
atic review on maintenance immunosuppression for adults un-
dergoing liver transplantation. We agree with Haddad 2006 that
tacrolimus appears to be superior to cyclosporine A. We also agree
with Fairfield 2015 that there is uncertainty about the role of glu-
cocorticosteroid therapy in immunosuppression. We were unable
to compare our findings with those of Penninga 2012, since the
trials included in Penninga 2012 did not report any of our out-
comes of interest.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Based on low-quality evidence from a single small trial from di-
rect comparison, tacrolimus plus sirolimus increases mortality
and graft loss at maximal follow-up compared with tacrolimus.
Based on very low-quality evidence from network meta-analy-
sis, we found no evidence of difference between immunosup-
pressive regimens. Based on very low-quality evidence from net-
work meta-analysis and low-quality evidence from direct compar-
ison, cyclosporine A causes more retransplantation compared with
tacrolimus.
Implications for research
Trials need to be conducted and reported according to the SPIRIT
(Standard Protocol Items: Recommendations for Interventional
Trials) statement, Chan 2013, and CONSORT statement (Schulz
2010). Future randomised clinical trials ought to be adequately
powered; performed in people who are generally seen in the clinic
rather than in highly selected participants; employ blinding; avoid
postrandomisation dropouts or planned cross-overs; and use clin-
ically important outcomes such as mortality, graft loss, renal im-
pairment, chronic kidney disease, and retransplantation. Such tri-
als should use tacrolimus as one of the control groups.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Asrani 2014
Methods Randomised clinical trial
Participants Country: International, multicentric
Number randomised: 222
Postrandomisation dropouts: 0 (0%)
Revised sample size: 222
Average age: 50 years
Females: 65 (29.3%)
Primary transplantation: 222 (100%)
Retransplantation: 0 (0%)
HCV: 72 (32.4%)
HBV: 30 (13.5%)
Alcoholic cirrhosis: 79 (35.6%)
Other causes: 40 (18%)
Average follow-up period in months (for all groups): 24
Additional treatment such as antiviral drugs: none stated
Important inclusion and exclusion criteria
Primary transplantation only: yes
Retransplantation only: no
HCV only: no
HBV only: no
Alcoholic cirrhosis only: no
Other causes: yes
Important exclusion criteria:
• Received systemic chemotherapy in the last 5 years
Interventions Participants were randomly assigned to 2 groups.
Group 1: sirolimus plus tacrolimus (n = 110).
Further details: sirolimus: IV to attain a trough level 4 to 11 ng/mL.
Tacrolimus: IV to attain 3 to 5 ng/mL.
Group 2: tacrolimus (n = 112).
Further details: tacrolimus: IV to attain 5 to 10 ng/mL.
Outcomes The outcomes reported were:
• mortality,
• graft loss,
• adverse events.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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Asrani 2014 (Continued)
Random sequence generation (selection
bias)
Low risk Quote: “computerized randomization”
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “participants, care providers and those assessing out-
comes were not blinded to randomized treatment assign-
ment”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “participants, care providers and those assessing out-
comes were not blinded to randomized treatment assign-
ment”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no postrandomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: no published protocol available; mortality/graft
loss and adverse events were reported
For-profit bias High risk Quote: “this study was conducted, monitored and paid for
by Wyeth, which was acquired by Pfizer in October 2009.”
Other bias Low risk Comment: no other bias noted.
Baiocchi 2006
Methods Randomised clinical trial
Participants Country: Italy
Number randomised: 20
Postrandomisation dropouts: 0 (0%)
Revised sample size: 20
Average age: 49 years
Females: 5 (25%)
Primary transplantation: 20 (100%)
Retransplantation: 0 (0%)
HCV: 8 (40%)
HBV: 4 (20%)
Alcoholic cirrhosis: 3 (15%)
Other causes: 1 (5%)
Average follow-up period in months (for all groups): 3
Additional treatment such as antiviral drugs: lamivudine in HBV patients
Important inclusion and exclusion criteria
Primary transplantation only: yes
Retransplantation only: no
HCV only: no
HBV only: no
Alcoholic cirrhosis only: no
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Baiocchi 2006 (Continued)
Other causes: yes
Other important inclusion criteria:
• Elective transplantation
Important exclusion criteria:
• Multi-organ transplantation
Interventions Participants were randomly assigned to 2 groups.
Group 1: cyclosporine A (n = 10).
Further details: cyclosporine A: attain 250 ng/mL.
Group 2: tacrolimus (n = 10).
Further details: tacrolimus: attain 10 ng/mL.
Outcomes None of the outcomes of interest were reported.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no postrandomisation dropouts.
Selective reporting (reporting bias) High risk Comment: no published protocol was available; either mor-
tality/graft loss or adverse events, or both were not reported
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other bias noted.
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Belli 1998
Methods Randomised clinical trial
Participants Country: Italy
Number randomised: 108
Postrandomisation dropouts: not stated
Revised sample size: 108
Average age: not stated
Females: not stated
Primary transplantation: 104 (96.3%)
Retransplantation: 0 (0%)
HCV: 42 (38.9%)
HBV: 24 (22.2%)
Alcoholic cirrhosis: 9 (8.3%)
Other causes: 21 (19.4%)
Average follow-up period in months (for all groups): 41
Additional treatment such as antiviral drugs: none stated
Important inclusion and exclusion criteria
Primary transplantation only: yes
Retransplantation only: no
HCV only: no
HBV only: no
Alcoholic cirrhosis only: no
Other causes: yes
Interventions Participants were randomly assigned to 2 groups.
Group 1: cyclosporine A plus glucocorticosteroids (n = 50).
Further details: cyclosporine A: attain 150 to 250 ng/mL; glucocorticosteroids: pred-
nisolone 0.1 mg/kg/day.
Group 2: cyclosporine A (n = 54).
Further details: cyclosporine A: attain 150 to 250 ng/mL.
Outcomes The outcomes reported were:
• mortality,
• adverse events,
• graft rejection.
Notes Reasons for postrandomisation dropouts: not stated.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
76Maintenance immunosuppression for adults undergoing liver transplantation: a network meta-analysis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Belli 1998 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) Low risk Comment: no published protocol was available; mortality/
graft loss and adverse events were reported
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other bias noted.
Boudjema 2011
Methods Randomised clinical trial
Participants Country: France
Number randomised: 195
Postrandomisation dropouts: 0 (0%)
Revised sample size: 195
Average age: 51 years
Females: 52 (26.7%)
Primary transplantation: 195 (100%)
Retransplantation: 0 (0%)
HCV: 16 (8.2%)
HBV: 4 (2.1%)
Alcoholic cirrhosis: 83 (42.6%)
Other causes: 91 (46.7%)
Average follow-up period in months (for all groups): 11
Additional treatment such as antiviral drugs: none stated
Important inclusion and exclusion criteria
Primary transplantation only: yes
Retransplantation only: no
HCV only: no
HBV only: no
Alcoholic cirrhosis only: no
Other causes: yes
Important exclusion criteria:
• Pregnancy
• Ongoing immunosuppressive treatment
• Donor-recipient blood group incompatibility
• Fulminant or autoimmune hepatitis, primary sclerosing cholangitis
77Maintenance immunosuppression for adults undergoing liver transplantation: a network meta-analysis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Boudjema 2011 (Continued)
• Combined transplantations
• Arterial hypertension treatment
• Diabetes treatment
• Hypercholesterolaemia treatment
• People with post-transplant plasma creatinine ≥ 200 µmol/L
Interventions Participants were randomly assigned to 2 groups.
Group 1: mycophenolate plus tacrolimus (n = 95).
Further details: mycophenolate: 1 g twice daily; tacrolimus: attain trough concentration
of <= 6 ng/mL.
Group 2: tacrolimus (n = 100).
Further details: tacrolimus: attain trough concentration of >= 6 ng/mL
Outcomes The outcomes reported were:
• mortality,
• graft loss,
• adverse events,
• renal impairment,
• retransplantation,
• graft rejection.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “the center-stratified randomization was based on
computer-generated lists”
Allocation concealment (selection bias) Low risk Quote: “randomization lists were kept by the pharmacist of
the coordinating center”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “since the trial was not blinded, the lists were bal-
anced by blocks of 24 patients in order to ensure total un-
predictability of the randomization sequence”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “since the trial was not blinded, the lists were bal-
anced by blocks of 24 patients in order to ensure total un-
predictability of the randomization sequence”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no postrandomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: no published protocol was available; mortality/
graft loss and adverse events were reported
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Boudjema 2011 (Continued)
For-profit bias Low risk Quote: “this study was conducted with financial support
from the FrenchMinistry of Health (2001 Clinical Research
Hospital Program, PHRC 2001)”
Other bias Low risk Comment: no other bias noted.
Chen 2002
Methods Randomised clinical trial
Participants Country: UK
Number randomised: 81
Postrandomisation dropouts: 0 (0%)
Revised sample size: 81
Average age: 49 years
Females: not stated
Primary transplantation: 81 (100%)
Retransplantation: 0 (0%)
HCV: 2 (2.5%)
HBV: 2 (2.5%)
Alcoholic cirrhosis: 6 (7.4%)
Other causes: 71 (87.7%)
Average follow-up period in months (for all groups): 124
Additional treatment such as antiviral drugs: none stated
Important inclusion and exclusion criteria
Primary transplantation only: yes
Retransplantation only: no
HCV only: no
HBV only: no
Alcoholic cirrhosis only: no
Other causes: yes
Important exclusion criteria:
• Vasculitis or arteritis
• Primary liver cancer with metastasis
• Active neoplastic disease
• HIV positive
• Multiple organ transplantation
• Treatment with an investigational agent with no safety data in the previous 28 days
• Total lymphoid irradiation in the previous 6 months
• Pregnant women or women not using adequate contraception
Interventions Participants were randomly assigned to 2 groups.
Group 1: cyclosporine A plus azathioprine (n = 41).
Further details: cyclosporine A: attain 100 to 200 ng/mL; azathioprine: 2 mg/kg/day.
Group 2: tacrolimus (n = 40).
Further details: tacrolimus: attain 0.5 to 1 ng/mL (plasma concentrations)
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Outcomes The outcomes reported were:
• mortality,
• graft loss,
• retransplantation.
Notes Thiswas part of the EuropeanFK506 trial, which includedmultiple centreswith different
centres using their own immunosuppressive regimen. This report is in patients from
Birmingham, UK. Some elements such as inclusion criteria and source of funding were
obtained from the multicentric report, although the results of the multicentric trial were
not included because of the different regimens used in different centres
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “open-label”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “open-label”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no postrandomisation dropouts.
Selective reporting (reporting bias) High risk Comment: no published protocol was available; either mor-
tality/graft loss or adverse events, or both were not reported
For-profit bias High risk Quote: “this study was sponsored by Fujisawa Pharmaceu-
tical Co Ltd, Osaka, Japan”
Other bias Low risk Comment: no other bias noted.
Cholongitas 2011
Methods Randomised clinical trial
Participants Country: UK
Number randomised: 66
Postrandomisation dropouts: 0 (0%)
Revised sample size: 66
Average age: 48 years
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Females: 27 (40.9%)
Primary transplantation: 66 (100%)
Retransplantation: 0 (0%)
HCV: not stated
HBV: not stated
Alcoholic cirrhosis: not stated
Other causes: not stated
Average follow-up period in months (for all groups): 97
Additional treatment such as antiviral drugs: none stated
Important inclusion and exclusion criteria
Primary transplantation only: yes
Retransplantation only: no
HCV only: not stated
HBV only: not stated
Alcoholic cirrhosis only: not stated
Other causes: not stated
Interventions Participants were randomly assigned to 2 groups.
Group 1: cyclosporine A (n = 36).
Further details: cyclosporine A: attain 100 to 300 ng/mL.
Group 2: tacrolimus (n = 30).
Further details: tacrolimus: attain 5 to 15 ng/mL.
Outcomes The outcomes reported were:
• mortality,
• graft loss,
• retransplantation,
• graft rejection.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “randomization was by using sealed opaque en-
velopes consecutively numbered and opened, containing the
allocated treatment code, derived from a random numbers
table”
Allocation concealment (selection bias) Low risk Quote: “randomization was by using sealed opaque en-
velopes consecutively numbered and opened, containing the
allocated treatment code, derived from a random numbers
table”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “open-label”
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Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “open-label”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no post-randomisation drop-outs.
Selective reporting (reporting bias) High risk Comment: no published protocol available; either mortal-
ity/graft loss or adverse events or both were not reported
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other bias noted.
De Simone 2012
Methods Randomised clinical trial
Participants Country: international, multicentric
Number randomised: 719
Postrandomisation dropouts: 0 (0%)
Revised sample size: 719
Average age: 54 years
Females: 196 (27.3%)
Primary transplantation: 719 (100%)
Retransplantation: 0 (0%)
HCV: 175 (24.3%)
HBV: 49 (6.8%)
Alcoholic cirrhosis: 171 (23.8%)
Other causes: 258 (35.9%)
Average follow-up period in months (for all groups): 36
Additional treatment such as antiviral drugs: none stated
Important inclusion and exclusion criteria
Primary transplantation only: yes
Retransplantation only: no
HCV only: no
HBV only: no
Alcoholic cirrhosis only: no
Other causes: yes
Other important inclusion criteria:
• Acceptable glomerular filtration rate
Important exclusion criteria:
• Hepatocellular carcinoma that did not fit the Milan criteria postexplant
Interventions Participants were randomly assigned to 3 groups.
Group 1: everolimus plus tacrolimus (n = 245).
Further details: everolimus: attain a trough concentration of 3 to 8 ng/mL; tacrolimus:
attain a trough concentration of 3 to 5 ng/mL.
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Group 2: everolimus (n = 231).
Further details: everolimus: attain a trough concentration of 6 to 10 ng/mL.
Group 3: tacrolimus (n = 243).
Further details: tacrolimus: attain a trough concentration of 6 to 10 ng/mL
Outcomes The outcomes reported were:
• mortality,
• graft loss,
• serious adverse events,
• adverse events,
• renal impairment,
• graft rejection.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “open-label”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “open-label”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no postrandomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: no published protocol was available; mortality/
graft loss and adverse events were reported
For-profit bias High risk Quote: “the study was funded by Novartis Pharma AG”
Other bias High risk Comment: recruitment to one of the intervention groups
was stopped early
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Fernandez-Miranda 1998
Methods Randomised clinical trial
Participants Country: Spain
Number randomised: 27
Postrandomisation dropouts: not stated
Revised sample size: 27
Average age: not stated
Females: not stated
Primary transplantation: not stated
Retransplantation: not stated
HCV: not stated
HBV: not stated
Alcoholic cirrhosis: not stated
Other causes: not stated
Average follow-up period in months (for all groups): 22
Additional treatment such as antiviral drugs: none stated
Important inclusion and exclusion criteria
Primary transplantation only: not stated
Retransplantation only: not stated
HCV only: not stated
HBV only: not stated
Alcoholic cirrhosis only: not stated
Other causes: not stated
Interventions Participants were randomly assigned to 2 groups.
Group 1: cyclosporine A (n = 14).
Further details: cyclosporine A: attain 100 to 250 ng/mL.
Group 2: tacrolimus (n = 13).
Further details: tacrolimus: attain 5 to 10 ng/mL.
Outcomes None of our outcomes of interest were reported.
Notes Reasons for postrandomisation dropouts: not stated
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
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Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) High risk Comment: either mortality/graft loss or adverse events, or
both were not reported
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other bias noted.
Fisher 1998
Methods Randomised clinical trial
Participants Country: USA
Number randomised: 99
Postrandomisation dropouts: 0 (0%)
Revised sample size: 99
Average age: 48 years
Females: 39 (39.4%)
Primary transplantation: 99 (100%)
Retransplantation: 0 (0%)
HCV: 37 (37.4%)
HBV: 7 (7.1%)
Alcoholic cirrhosis: 11 (11.1%)
Other causes: 44 (44.4%)
Average follow-up period in months (for all groups): 48
Additional treatment such as antiviral drugs: none stated
Important inclusion and exclusion criteria
Primary transplantation only: yes
Retransplantation only: no
HCV only: no
HBV only: no
Alcoholic cirrhosis only: no
Other causes: yes
Interventions Participants were randomly assigned to 2 groups.
Group 1: cyclosporine A plus mycophenolate (n = 50).
Further details: cyclosporine A: attain 200 to 300 ng/mL; mycophenolate mofetil: 1 g/
day.
Group 2: tacrolimus plus mycophenolate (n = 49).
Further details: tacrolimus: attain 5 to 10 ng/mL; mycophenolate mofetil: 1 g/day
Outcomes
Notes
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Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “open-label”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “open-label”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no postrandomisation dropouts.
Selective reporting (reporting bias) High risk Comment: no published protocol was available; either mor-
tality/graft loss or adverse events, or both were not reported
For-profit bias High risk Quote: “this study was supported in part by a grant from
Hoffman, LaRoche Inc.”
Other bias Low risk Comment: no other bias noted.
Fung 1991
Methods Randomised clinical trial
Participants Country: USA
Number randomised: 81
Postrandomisation dropouts: not stated
Revised sample size: 81
Average age: 42 years
Females: 33 (40.7%)
Primary transplantation: 81 (100%)
Retransplantation: 0 (0%)
HCV: not stated
HBV: 0 (0%)
Alcoholic cirrhosis: not stated
Other causes: not stated
Average follow-up period in months (for all groups): 12
Additional treatment such as antiviral drugs: none stated
Important inclusion and exclusion criteria
Primary transplantation only: yes
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Retransplantation only: no
HCV only: not stated
HBV only: no
Alcoholic cirrhosis only: not stated
Other causes: not stated
Important exclusion criteria:
• People with cancer
• People undergoing multiple organ transplantation
• People with pre-existing renal failure
• Active infection
• Stage 4 coma, defined as unconscious and ventilator dependent
• Clinically significant heart or lung disease
• Previous reconstructive or bypass procedures of the liver
• Technically unsatisfactory operations with poor immediate liver function
Interventions Participants were randomly assigned to 2 groups.
Group 1: cyclosporine A (n = 40).
Further details: cyclosporine A: attain 600 to 800 ng/mL.
Group 2: tacrolimus (n = 41).
Further details: tacrolimus: attain 1 to 5 ng/mL.
Outcomes The outcomes reported were:
• mortality,
• graft loss,
• adverse events,
• renal impairment,
• retransplantation,
• graft rejection.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “treatment assignment was determined by a com-
puter program implementing the block randomization tech-
nique, to assure that the treatment groups remained reason-
ably balanced”
Allocation concealment (selection bias) Low risk Quote: “a sealed envelope method was implemented. Each
envelope contained a single treatment assignment”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) Low risk Comment: no published protocol available; mortality/graft
loss and adverse events were reported
For-profit bias Low risk Quote: “this work was supported by research grant OK
29961 from the National Institutes of Health, Bethesda,
Maryland, and the Veterans Administration”
Other bias Low risk Comment: no other bias noted.
Greig 2003
Methods Randomised clinical trial
Participants Country: Canada
Number randomised: 143
Postrandomisation dropouts: 0 (0%)
Revised sample size: 143
Average age: 50 years
Females: 56 (39.2%)
Primary transplantation: 139 (97.2%)
Retransplantation: 4 (2.8%)
HCV: 47 (32.9%)
HBV: 0 (0%)
Alcoholic cirrhosis: 25 (17.5%)
Other causes: 67 (46.9%)
Average follow-up period in months (for all groups): 12
Additional treatment such as antiviral drugs: none stated
Important inclusion and exclusion criteria
Primary transplantation only: no
Retransplantation only: no
HCV only: no
HBV only: no
Alcoholic cirrhosis only: no
Other causes: yes
Important exclusion criteria:
• HIV positive
• Hepatocellular carcinoma above stage III TNM
• Multivisceral transplantation
• ABO incompatibility
• Renal failure
• Acute pancreatitis
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• Post-transplant life expectancy <= 2 weeks
Interventions Participants were randomly assigned to 2 groups.
Group 1: cyclosporine A (n = 72).
Further details: cyclosporine A: attain 100 to 250 ng/mL.
Group 2: tacrolimus (n = 71).
Further details: tacrolimus: attain 5 to 15 ng/mL.
Outcomes The outcomes reported were:
• mortality,
• graft loss,
• adverse events,
• renal impairment,
• retransplantation,
• graft rejection.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “open-label”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “open-label”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no postrandomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: no published protocol was available; mortality/
graft loss and adverse events were reported
For-profit bias High risk Quote: “Supported by Fujisawa Canada, Inc”
Other bias Low risk Comment: no other bias noted.
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Jain 2001
Methods Randomised clinical trial
Participants Country: USA
Number randomised: 350
Postrandomisation dropouts: 0 (0%)
Revised sample size: 350
Average age: 52 years
Females: 148 (42.3%)
Primary transplantation: 350 (100%)
Retransplantation: 0 (0%)
HCV: 95 (27.1%)
HBV: 15 (4.3%)
Alcoholic cirrhosis: 70 (20%)
Other causes: 160 (45.7%)
Average follow-up period in months (for all groups): 34
Additional treatment such as antiviral drugs: none stated
Important inclusion and exclusion criteria
Primary transplantation only: yes
Retransplantation only: no
HCV only: no
HBV only: no
Alcoholic cirrhosis only: no
Other causes: yes
Interventions Participants were randomly assigned to 2 groups.
Group 1: tacrolimus plus mycophenolate plus glucocorticosteroids (n = 175).
Further details: tacrolimus: attain 10 to 15 ng/mL; mycophenolate mofetil: 1 g twice
daily; glucocorticosteroids: methyl prednisolone 20 mg/day.
Group 2: tacrolimus plus glucocorticosteroids (n = 175).
Further details: tacrolimus: attain 10 to 15 ng/mL; glucocorticosteroids: methyl pred-
nisolone 20 mg/day
Outcomes The outcomes reported were:
• mortality,
• graft loss,
• renal impairment,
• retransplantation,
• graft rejection.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “randomizationwas based on a sequential draw of as-
signments using a variable block randomization procedure”
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Allocation concealment (selection bias) Low risk Quote: “the statisticians gave sealed envelopes to clinicians.
”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “open-label”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “open-label”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no postrandomisation dropouts.
Selective reporting (reporting bias) High risk Comment: no published protocol was available; either mor-
tality/graft loss or adverse events, or both were not reported
For-profit bias Unclear risk Quote: “supported in part by research grants from the Vet-
erans Administration and project grant no. DK-29961 from
The National Institutes of Health, Bethesda, MD”
Comment: it is not clear if additional funding was received
from drug manufacturers
Other bias Low risk Comment: no other bias noted.
Jonas 2005
Methods Randomised clinical trial
Participants Country: Germany
Number randomised: 121
Postrandomisation dropouts: 0 (0%)
Revised sample size: 121
Average age: 48 years
Females: 71 (58.7%)
Primary transplantation: 121 (100%)
Retransplantation: 0 (0%)
HCV: 35 (28.9%)
HBV: 30 (24.8%)
Alcoholic cirrhosis: 20 (16.5%)
Other causes: 37 (30.6%)
Average follow-up period in months (for all groups): 144
Additional treatment such as antiviral drugs: none stated
Important inclusion and exclusion criteria
Primary transplantation only: yes
Retransplantation only: no
HCV only: no
HBV only: no
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Alcoholic cirrhosis only: no
Other causes: yes
Important exclusion criteria:
• Vasculitis or arteritis
• Primary liver cancer with metastasis
• Active neoplastic disease
• HIV positive
• Multiple organ transplantation
• Treatment with an investigational agent with no safety data in the previous 28 days
• Total lymphoid irradiation in the previous 6 months
• Pregnant women or women not using adequate contraception
Interventions Participants were randomly assigned to 2 groups.
Group 1: cyclosporine A plus azathioprine (n = 60).
Further details: cyclosporine A: attain 600 to 900 ng/mL; azathioprine: 1 to 2 mg/kg/
day.
Group 2: tacrolimus (n = 61).
Further details: tacrolimus: 0.10 to 0.15 mg/kg/day.
Outcomes The outcomes reported were:
• mortality,
• graft loss,
• retransplantation,
• graft rejection.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “open-label”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “open-label”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no postrandomisation dropouts.
Selective reporting (reporting bias) High risk Comment: no published protocol was available; either mor-
tality/graft loss or adverse events, or both were not reported
92Maintenance immunosuppression for adults undergoing liver transplantation: a network meta-analysis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Jonas 2005 (Continued)
For-profit bias High risk Quote: “this study was sponsored by Fujisawa Pharmaceu-
tical Co Ltd, Osaka, Japan”
Other bias Low risk Comment: no other bias noted.
Loinaz 2001
Methods Randomised clinical trial
Participants Country: Spain
Number randomised: 101
Postrandomisation dropouts: 1 (1%)
Revised sample size: 100
Average age: 50 years
Females: 31 (31%)
Primary transplantation: 100 (100%)
Retransplantation: 0 (0%)
HCV: not stated
HBV: not stated
Alcoholic cirrhosis: not stated
Other causes: not stated
Average follow-up period in months (for all groups): 24
Additional treatment such as antiviral drugs: none stated
Important inclusion and exclusion criteria
Primary transplantation only: yes
Retransplantation only: no
HCV only: no
HBV only: not stated
Alcoholic cirrhosis only: no
Other causes: yes
Important exclusion criteria:
• More than 1 transplantation
• Participation in another immunosuppression study
Interventions Participants were randomly assigned to 2 groups.
Group 1: cyclosporine A (n = 49).
Further details: cyclosporine A: attain 100 to 150 ng/mL.
Group 2: tacrolimus (n = 51).
Further details: tacrolimus: attain 5 to 8 ng/mL.
Outcomes The outcomes reported were:
• mortality,
• graft loss,
• adverse events,
• graft rejection.
Notes Reasons for postrandomisation dropouts: not stated
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Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “open-label”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “open-label”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: there were postrandomisation dropouts, but the
reasons for them were not reported
Selective reporting (reporting bias) Low risk Comment: mortality/graft loss and adverse events were re-
ported
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other bias noted.
Manousou 2014
Methods Randomised clinical trial
Participants Country: UK
Number randomised: 103
Postrandomisation dropouts: 6 (5.8%)
Revised sample size: 97
Average age: 49 years
Females: 29 (29.9%)
Primary transplantation: 97 (100%)
Retransplantation: 0 (0%)
HCV: 97 (100%)
HBV: 0 (0%)
Alcoholic cirrhosis: 0 (0%)
Other causes: 0 (0%)
Average follow-up period in months (for all groups): 96
Additional treatment such as antiviral drugs: none stated
Important inclusion and exclusion criteria
Primary transplantation only: yes
Retransplantation only: no
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HCV only: yes
HBV only: no
Alcoholic cirrhosis only: no
Other causes: no
Important exclusion criteria:
• Multi-organ transplant
• Split or auxiliary transplant
• Contraindications to tacrolimus or azathioprine
Interventions Participants were randomly assigned to 2 groups.
Group 1: tacrolimus plus azathioprine (n = 48).
Further details: tacrolimus: attain 5 to 10 ng/mL; azathioprine: 1 mg/kg/day.
Group 2: tacrolimus (n = 49).
Further details: tacrolimus: attain 5 to 10 ng/mL.
Outcomes The outcomes reported were:
• mortality,
• graft loss,
• retransplantation,
• graft rejection.
Notes Reasons for postrandomisation dropouts: early complications, early retransplantation
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “for randomization, sealed opaque envelopes were
used; they were opened in a numbered sequence containing
the allocated treatment in a 1:1 proportion derived from a
random number table with a blocked code for each center”
Allocation concealment (selection bias) Low risk Quote: “for randomization, sealed opaque envelopes were
used; they were opened in a numbered sequence containing
the allocated treatment in a 1:1 proportion derived from a
random number table with a blocked code for each center”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were postrandomisation dropouts, which
were related to treatment complications
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Selective reporting (reporting bias) High risk Comment: no published protocol was available; either mor-
tality/graft loss or adverse events, or both were not reported
For-profit bias High risk Quote: “AKB and APD have an unrestricted educational
grant from Pfizer.”
Other bias Low risk Comment: no other bias noted.
Martin 2004
Methods Randomised clinical trial
Participants Country: USA
Number randomised: 85
Postrandomisation dropouts: 6 (7.1%)
Revised sample size: 79
Average age: 50 years
Females: 29 (36.7%)
Primary transplantation: 79 (100%)
Retransplantation: 0 (0%)
HCV: 79 (100%)
HBV: 0 (0%)
Alcoholic cirrhosis: 0 (0%)
Other causes: 0 (0%)
Average follow-up period in months (for all groups): 12
Additional treatment such as antiviral drugs: no antiviral therapy
Important inclusion and exclusion criteria
Primary transplantation only: yes
Retransplantation only: no
HCV only: yes
HBV only: no
Alcoholic cirrhosis only: no
Other causes: no
Important exclusion criteria:
• ABO incompatibility
• Pregnancy
• Presence of hepatocellular carcinoma prior to transplant
• Presence of HBV antigen
• Immunosuppression with other medications besides those in the protocol
• Multi-organ transplant
• HIV infection
• Renal dialysis
Interventions Participants were randomly assigned to 2 groups.
Group 1: cyclosporine A plus glucocorticosteroids (n = 41).
Further details: cyclosporine A: attain 100 to 250 ng/mL; glucocorticosteroids: pred-
nisolone 5 mg/day.
Group 2: tacrolimus plus glucocorticosteroids (n = 38).
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Further details: tacrolimus: attain 5 to 10 ng/mL; glucocorticosteroids: prednisolone 5
mg/day
Outcomes The outcomes reported were:
• mortality,
• graft rejection.
Notes Reasons for postrandomisation dropouts: did not receive transplant or did not meet
inclusion/exclusion criteria
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “prior to transplant, patients were assigned by a tele-
phone randomization system to receive either tac-rolimus
or cyclosporine (Neoral) maintenance therapy beginning 12
hours after transplant”
Allocation concealment (selection bias) Low risk Quote: “prior to transplant, patients were assigned by a tele-
phone randomization system to receive either tac-rolimus
or cyclosporine (Neoral) maintenance therapy beginning 12
hours after transplant”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “open-label”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “open-label”
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: there were post-randomisation drop-outs. Many
were related to potential complications of treatment
Selective reporting (reporting bias) High risk Comment: no published protocol available; either mortal-
ity/graft loss or adverse events or both were not reported
For-profit bias High risk Quote: “supported by an educational grant from Fujisawa
Healthcare, Inc., Deerfield, IL”
Other bias Low risk Comment: no other bias noted.
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Methods Randomised clinical trial
Participants Country: Italy
Number randomised: 78
Postrandomisation dropouts: 0 (0%)
Revised sample size: 78
Average age: 54 years
Females: 18 (23.1%)
Primary transplantation: 78 (100%)
Retransplantation: 0 (0%)
HCV: not stated
HBV: not stated
Alcoholic cirrhosis: not stated
Other causes: not stated
Average follow-up period in months (for all groups): 22
Additional treatment such as antiviral drugs: none stated
Important inclusion and exclusion criteria
Primary transplantation only: yes
Retransplantation only: no
HCV only: not stated
HBV only: not stated
Alcoholic cirrhosis only: not stated
Other causes: not stated
Important exclusion criteria:
• HIV positive
• Women who were pregnant or breastfeeding
• Recipients of multiple-organ transplant
• ABO-incompatible transplants
• Living-related or -unrelated donor transplants
• People with thrombocytopenia, leukopenia, hypercholesterolaemia, or
hypertriglyceridaemia
• Renal failure
Interventions Participants were randomly assigned to 2 groups.
Group 1: everolimus (n = 52).
Further details: everolimus: attain 6 to 10 ng/mL.
Group 2: cyclosporine A (n = 26).
Further details: cyclosporine A: attain 125 to 175 ng/mL.
Outcomes The outcomes reported were:
• mortality,
• adverse events,
• graft rejection.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “open-label”.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “open-label”.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no post-randomisation drop-outs.
Selective reporting (reporting bias) Low risk Comment: no published protocol available; mortality/graft
loss and adverse events were reported
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other bias noted.
O’Grady 2002
Methods Randomised clinical trial
Participants Country: international, multicentric
Number randomised: 606
Postrandomisation dropouts: 0 (0%)
Revised sample size: 606
Average age: 51 years
Females: 256 (42.2%)
Primary transplantation: 606 (100%)
Retransplantation: 0 (0%)
HCV: 60 (9.9%)
HBV: 20 (3.3%)
Alcoholic cirrhosis: 110 (18.2%)
Other causes: 98 (16.2%)
Average follow-up period in months (for all groups): 36
Additional treatment such as antiviral drugs: none stated
Important inclusion and exclusion criteria
Primary transplantation only: yes
Retransplantation only: no
HCV only: no
HBV only: no
Alcoholic cirrhosis only: no
Other causes: yes
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Important exclusion criteria:
• Multi-organ transplantation
• Auxiliary grafts
• Incompatible donor blood group
• Pregnancy
• Breastfeeding
• Contraindications to the study drugs
• If the person expected to move or return to a country where either drug was not
available
• Patient’s refusal
Interventions Participants were randomly assigned to 2 groups.
Group 1: cyclosporine A (n = 305).
Further details: cyclosporine A: attain 150 to 250 ng/mL.
Group 2: tacrolimus (n = 301).
Further details: tacrolimus: attain 5 to 15 ng/mL.
Outcomes The outcomes reported were:
• mortality,
• graft loss,
• adverse events,
• renal impairment,
• retransplantation,
• graft rejection.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “the data coordinating centre at the Medical Statis-
tics Unit at the London School of Hygiene and Tropical
Medicine generated stratified and blocked randomised se-
quences using computer-generated random numbers”
Allocation concealment (selection bias) Low risk Quote: “cards, with details of treatment allocation on, were
put in serially numbered, opaque envelopes and sent to each
centre”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “open-label”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “open-label”
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Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no postrandomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: no published protocol was available; mortality/
graft loss and adverse events were reported
For-profit bias High risk Quote: “Fujisawa and Novartis both approved the protocol,
received interim reports simultaneously, and commented on
the manuscript before submission for publication”
Other bias High risk Comment: trial was stopped early for benefit.
Pageaux 2004
Methods Randomised clinical trial
Participants Country: France
Number randomised: 174
Postrandomisation dropouts: 0 (0%)
Revised sample size: 174
Average age: 52 years
Females: 50 (28.7%)
Primary transplantation: 174 (100%)
Retransplantation: 0 (0%)
HCV: 26 (14.9%)
HBV: 12 (6.9%)
Alcoholic cirrhosis: 84 (48.3%)
Other causes: 52 (29.9%)
Average follow-up period in months (for all groups): 6
Additional treatment such as antiviral drugs: none stated
Important inclusion and exclusion criteria
Primary transplantation only: yes
Retransplantation only: no
HCV only: no
HBV only: no
Alcoholic cirrhosis only: no
Other causes: yes
Interventions Participants were randomly assigned to 2 groups.
Group 1: cyclosporine A plus glucocorticosteroids (n = 90).
Further details: cyclosporine A: attain 150 to 300 ng/mL; glucocorticosteroids: pred-
nisolone 20 mg/day.
Group 2: cyclosporine A (n = 84).
Further details: cyclosporine A: attain 150 to 300 ng/mL.
Outcomes The outcomes reported were:
• mortality,
• adverse events,
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• graft rejection.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “double-blind, placebo-controlled study”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “double-blind, placebo-controlled study”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no postrandomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: no published protocol was available; mortality/
graft loss and adverse events were reported
For-profit bias High risk Quote: “supported by a grant from Novartis Pharma”
Other bias High risk Comment: despite following participants for 12months, the
authors present only the 6-month results and have excluded
2 late deaths
Pelletier 2013
Methods Randomised clinical trial
Participants Country: USA
Number randomised: 100
Postrandomisation dropouts: 0 (0%)
Revised sample size: 100
Average age: 55 years
Females: 24 (24%)
Primary transplantation: 100 (100%)
Retransplantation: 0 (0%)
HCV: 54 (54%)
HBV: not stated
Alcoholic cirrhosis: 42 (42%)
Other causes: 4 (4%)
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Average follow-up period in months (for all groups): 69
Additional treatment such as antiviral drugs: none stated
Important inclusion and exclusion criteria
Primary transplantation only: yes
Retransplantation only: no
HCV only: no
HBV only: no
Alcoholic cirrhosis only: not stated
Other causes: yes
Important exclusion criteria:
• Multiple-organ transplant recipients
• Required steroid therapy for reasons other than immunosuppression (e.g.
autoimmune hepatitis or inflammatory bowel disease)
Interventions Participants were randomly assigned to 2 groups.
Group 1: tacrolimus plus mycophenolate plus glucocorticosteroids (n = 50).
Further details: tacrolimus: dosage not stated; mycophenolate mofetil: dosage not stated;
glucocorticosteroids: tapering dose (dose not stated).
Group 2: tacrolimus plus mycophenolate (n = 50).
Further details: tacrolimus: dosage not stated; mycophenolate mofetil: dosage not stated
Outcomes The outcomes reported were:
• adverse events,
• renal impairment,
• chronic kidney disease,
• retransplantation,
• graft rejection.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Quote: “enrolled candidates were randomized to either the
’steroids’ or ’no-steroids’ groups using a closed-envelope sys-
tem”
Comment: further information about the closed-envelope
system was not available
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “open-label”
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Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “open-label”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no postrandomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: no published protocol was available; mortality/
graft loss and adverse events were reported
For-profit bias High risk Quote: “this study was supported by a grant from Astellas
Pharma, Inc., Deerfield, IL, USA”
Other bias Low risk Comment: no other bias noted.
Pham 1998
Methods Randomised clinical trial
Participants Country: France
Number randomised: 88
Postrandomisation dropouts: 12 (13.6%)
Revised sample size: 76
Average age: not stated
Females: not stated
Primary transplantation: 76 (100%)
Retransplantation: 0 (0%)
HCV: not stated
HBV: not stated
Alcoholic cirrhosis: not stated
Other causes: not stated
Average follow-up period in months (for all groups): 27
Additional treatment such as antiviral drugs: none stated
Important inclusion and exclusion criteria
Primary transplantation only: yes
Retransplantation only: no
HCV only: not stated
HBV only: not stated
Alcoholic cirrhosis only: not stated
Other causes: not stated
Important exclusion criteria:
• Renal failure before transplantation
Interventions Participants were randomly assigned to 2 groups.
Group 1: cyclosporine A plus azathioprine plus glucocorticosteroids (n = 38).
Further details: cyclosporine: 1 to 6 mg/kg/day; azathioprine: 2 mg/kg/day; glucocorti-
costeroids: methyl prednisolone 0.3 mg/kg/day.
Group 2: tacrolimus plus glucocorticosteroids (n = 38).
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Further details: tacrolimus: 0.3 mg/kg/day; glucocorticosteroids: methyl prednisolone
20 mg/day tapering dose
Outcomes None of our outcomes of interest were reported.
Notes Reasons for postrandomisation dropouts: died postoperatively or cross-over
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “open-label”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “open-label”
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: participants were excluded because of death or
cross-over. This will introduce bias
Selective reporting (reporting bias) High risk Comment: no published protocol was available; either mor-
tality/graft loss or adverse events, or both were not reported
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other bias noted.
Porayko 1994
Methods
Participants Country: USA
Number randomised: 37
Postrandomisation dropouts: 0 (0%)
Revised sample size: 37
Average age: 49 years
Females: 14 (37.8%)
Primary transplantation: 37 (100%)
Retransplantation: 0 (0%)
HCV: not stated
HBV: not stated
105Maintenance immunosuppression for adults undergoing liver transplantation: a network meta-analysis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Porayko 1994 (Continued)
Alcoholic cirrhosis: 6 (16.2%)
Other causes: 29 (78.4%)
Average follow-up period in months (for all groups): 12
Additional treatment such as antiviral drugs: none stated
Important inclusion and exclusion criteria
Primary transplantation only: yes
Retransplantation only: no
HCV only: not stated
HBV only: no
Alcoholic cirrhosis only: no
Other causes: yes
Important exclusion criteria:
• Poor renal function before transplantation
• Had hepatocellular carcinoma
Interventions Participants were randomly assigned to 2 groups.
Group 1: cyclosporine A plus azathioprine plus glucocorticosteroids (n = 17).
Further details: cyclosporine: attain 100 to 200 ng/mL; azathioprine: 2 mg/kg/day;
glucocorticosteroids: prednisolone 10 mg/day.
Group 2: tacrolimus plus glucocorticosteroids (n = 20).
Further details: tacrolimus: attain 0.2 to 5 ng/mL; glucocorticosteroids: prednisolone 5
mg/day
Outcomes The outcomes reported were:
• mortality,
• adverse events,
• renal impairment,
• retransplantation,
• graft rejection.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “open-label”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “open-label”
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Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no postrandomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: no published protocol was available; mortality/graft
loss and adverse events were reported
For-profit bias High risk Quote: “this studywas supported by a grant fromFujisawa Phar-
maceutical Company, Deerfield, Illinois.”
Other bias Low risk Comment: no other bias noted.
Shenoy 2008
Methods Randomised clinical trial
Participants Country: USA
Number randomised: 60
Postrandomisation dropouts: 0 (0%)
Revised sample size: 60
Average age: 53 years
Females: 20 (33.3%)
Primary transplantation: not stated
Retransplantation: not stated
HCV: 32 (53.3%)
HBV: 5 (8.3%)
Alcoholic cirrhosis: 8 (13.3%)
Other causes: 16 (26.7%)
Average follow-up period in months (for all groups): 12
Additional treatment such as antiviral drugs: none stated
Important inclusion and exclusion criteria
Primary transplantation only: not stated
Retransplantation only: not stated
HCV only: no
HBV only: no
Alcoholic cirrhosis only: no
Other causes: yes
Important exclusion criteria:
• Known allergy to cyclosporine A
• Malignancy within the last 2 years
• Women of childbearing potential not practicing a reliable form of birth control
• People with active infection
Interventions Participants were randomly assigned to 2 groups.
Group 1: cyclosporine A (n = 30).
Further details: cyclosporine A: attain 600 to 1000 ng/mL at 2 hours (C2).
Group 2: tacrolimus (n = 30).
Further details: tacrolimus: attain 5 to 10 ng/mL.
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Outcomes The outcomes reported were:
• mortality,
• graft loss,
• adverse events,
• retransplantation,
• graft rejection.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no postrandomisation dropouts.
Selective reporting (reporting bias) Low risk Comment: no published protocol was available; mortality/
graft loss and adverse events were reported
For-profit bias High risk Quote: “supported by a research grant from Novartis”
Other bias Low risk Comment: no other bias noted.
Stegall 1997
Methods Randomised clinical trial
Participants Country: USA
Number randomised: 71
Postrandomisation dropouts: 0 (0%)
Revised sample size: 71
Average age: not stated
Females: not stated
Primary transplantation: not stated
Retransplantation: not stated
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HCV: not stated
HBV: 0 (0%)
Alcoholic cirrhosis: not stated
Other causes: not stated
Average follow-up period in months (for all groups): 6
Additional treatment such as antiviral drugs: no
Important inclusion and exclusion criteria
Primary transplantation only: not stated
Retransplantation only: not stated
HCV only: no
HBV only: no
Alcoholic cirrhosis only: not stated
Other causes: not stated
Interventions Participants were randomly assigned to 2 groups.
Group 1: cyclosporine A (n = 36).
Further details: cyclosporine A: attain 200 to 250 ng/mL.
Group 2: tacrolimus (n = 35).
Further details: tacrolimus: attain 8 to 10 ng/mL.
Outcomes The outcomes reported were:
• mortality,
• graft loss,
• adverse events,
• graft rejection.
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quote: “open-label”
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “open-label”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: there were no postrandomisation dropouts.
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Selective reporting (reporting bias) Low risk Comment: no published protocol was available; mortality/
graft loss and adverse events were reported
For-profit bias Unclear risk Comment: this information was not available.
Other bias Low risk Comment: no other bias noted.
Sterneck 2000
Methods Randomised clinical trial
Participants Country: Germany
Number randomised: 57
Postrandomisation dropouts: not stated
Revised sample size: 57
Average age: not stated
Females: not stated
Primary transplantation: 57 (100%)
Retransplantation: 0 (0%)
HCV: not stated
HBV: not stated
Alcoholic cirrhosis: not stated
Other causes: not stated
Average follow-up period in months (for all groups): 6
Additional treatment such as antiviral drugs: none stated
Important inclusion and exclusion criteria
Primary transplantation only: yes
Retransplantation only: no
HCV only: no
HBV only: not stated
Alcoholic cirrhosis only: not stated
Other causes: not stated
Important exclusion criteria:
• People with cancer
• Gastrointestinal ulcer
Interventions Participants were randomly assigned to 2 groups.
Group 1: cyclosporine A plus mycophenolate plus glucocorticosteroids (n = 28).
Further details: cyclosporine A: attain 100 to 150 ng/mL; mycophenolate mofetil: 1 to
1.5 g twice daily; glucocorticosteroids: 6 mg/day.
Group 2: cyclosporine A plus azathioprine plus glucocorticosteroids (n = 29).
Further details: cyclosporine A: attain 100 to 150 ng/mL; azathioprine: 1 to 2 mg/kg/
day; glucocorticosteroids: 6 mg/day
Outcomes The outcomes reported were:
• mortality,
• graft loss,
• adverse events,
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• graft rejection.
Notes Reasons for postrandomisation dropouts: not stated
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: this information was not available.
Selective reporting (reporting bias) Low risk Comment: no published protocol was available; mortality/
graft loss and adverse events were reported
For-profit bias High risk Quote: “the present work was partly supported by the com-
pany Hoffmann La Roche, Grenzach Whylen”
Other bias Low risk Comment: no other bias noted.
Zervos 1998
Methods Randomised clinical trial
Participants Country: USA
Number randomised: 50
Postrandomisation dropouts: 1 (2%)
Revised sample size: 49
Average age: 49 years
Females: 23 (46.9%)
Primary transplantation: not stated
Retransplantation: not stated
HCV: 49 (100%)
HBV: 0 (0%)
Alcoholic cirrhosis: 0 (0%)
Other causes: 0 (0%)
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Average follow-up period in months (for all groups): 14
Additional treatment such as antiviral drugs: yes (interferon therapy)
Important inclusion and exclusion criteria
Primary transplantation only: not stated
Retransplantation only: not stated
HCV only: yes
HBV only: no
Alcoholic cirrhosis only: no
Other causes: no
Interventions Participants were randomly assigned to 2 groups.
Group 1: cyclosporine A (n = 24).
Further details: cyclosporine A: attain 300 to 400 ng/mL.
Group 2: tacrolimus (n = 25).
Further details: tacrolimus: attain 15 ng/mL.
Outcomes The outcomes reported were:
• mortality,
• graft loss,
• adverse events,
• retransplantation,
• graft rejection.
Notes Reasons for postrandomisation dropouts: not stated
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: this information was not available.
Allocation concealment (selection bias) Unclear risk Comment: this information was not available.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: this information was not available.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: this information was not available.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: there were postrandomisation dropouts, but the
reasons for them were not stated
Selective reporting (reporting bias) Low risk Comment: no published protocol was available; mortality/
graft loss and adverse events were reported
For-profit bias Unclear risk Comment: this information was not available.
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Other bias Low risk Comment: no other bias noted.
HBV: hepatitis B virus
HCV: hepatitis C virus
IV: intravenous
TNM: Tumor, Node, Metastasis
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abdelmalek 2012 No fixed immunosuppression regimen in either intervention group or control group, or both
Barnes 1997 Not on maintenance immunosuppression
Beckebaum 2004 No fixed immunosuppression regimen in either intervention group or control group, or both
Becker 2008 Not on maintenance immunosuppression
Benitez 2010 Not on maintenance immunosuppression
Berenguer 2006 Randomisation was performed at least 1 year after liver transplantation
Biancofiore 2004 Not on maintenance immunosuppression
Bilbao 2009 Not on maintenance immunosuppression
Bogetti 2005 Not on maintenance immunosuppression
Boillot 2000 Not on maintenance immunosuppression
Boillot 2001 Not on maintenance immunosuppression
Boillot 2005 Not on maintenance immunosuppression
Boillot 2009 Not on maintenance immunosuppression
Boleslawski 2004 Details of maintenance immunosuppression not available.
Calmus 2010 Not on maintenance immunosuppression
Chen 2005 Comparison of different regimens of same drug
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Cicinnati 2007 Randomisation was performed at least 1 year after liver transplantation
Cillo 2014 Details of maintenance immunosuppression not available.
Cosimi 1987 Not on maintenance immunosuppression
Cosimi 1990 Not on maintenance immunosuppression
Cuervas-Mons 2015 Not on maintenance immunosuppression
Day 2004 Details of maintenance immunosuppression not available.
De Simone 2009 No fixed immunosuppression regimen in either intervention group or control group, or both
De Simone 2015 Comparison of different regimens of same drug
Duvoux 2015 Randomisation was performed from 6 months to 10 years.
Eason 2003 Not on maintenance immunosuppression
Ericzon 1997 Not on maintenance immunosuppression
Farges 1994 Not on maintenance immunosuppression
Filipponi 2004 Not on maintenance immunosuppression
Firpi 2006 Not a randomised clinical trial
Firpi 2010 Randomisation was performed only after recurrence of hepatitis C infection
Fischer 2012 No fixed immunosuppression regimen in either intervention group or control group, or both
Fleckenstein 1996 Not on maintenance immunosuppression
Garcia Gonzalez 2005 Not on maintenance immunosuppression
Garcia-Saenz-de-Sicilia 2014 Not on maintenance immunosuppression
Geissler 2016 No fixed immunosuppression regimen in either intervention group or control group, or both
Gerhardt 2009 No fixed immunosuppression regimen in either intervention group or control group, or both
Gonzalez-Pinto 2005 Although this is a long-term report of an included study (Loinaz 2001), after the randomisation
period was complete, immunosuppression was left to local centre’s protocol
Grant 2012 Not on maintenance immunosuppression
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Hardinger 2004 Details of maintenance immunosuppression not available.
Herlenius 2010 No fixed immunosuppression regimen in either intervention group or control group, or both
Hodge 2002 Randomisation was performed between 3 months and 27 months after liver transplantation
Hytiroglou 1993 Details of maintenance immunosuppression not available.
Junge 2005 Randomisation was performed at least 1 year after liver transplantation
Kato 2007 Not on maintenance immunosuppression
Keiding 1997 Not on maintenance immunosuppression
Klintmalm 1994 No fixed immunosuppression regimen in either intervention group or control group. or both
Klintmalm 2007 No fixed immunosuppression regimen in either intervention group or control group, or both
Klintmalm 2014 No fixed immunosuppression regimen in either intervention group or control group, or both
Klupp 1998 Not on maintenance immunosuppression
Langrehr 1997 Not on maintenance immunosuppression
Langrehr 1998a Not on maintenance immunosuppression
Langrehr 1998b Not on maintenance immunosuppression
Langrehr 2001 Not on maintenance immunosuppression
Langrehr 2002 Not on maintenance immunosuppression
Lerut 2005 Not on maintenance immunosuppression
Lerut 2008 Not on maintenance immunosuppression
Levy 2004 No fixed immunosuppression regimen in either intervention group or control group, or both
Levy 2006 No fixed immunosuppression regimen in either intervention group or control group, or both
Levy 2014 No fixed immunosuppression regimen in either intervention group or control group, or both
Llado 2006 Details of maintenance immunosuppression not available.
Llado 2014 Details of maintenance immunosuppression not available.
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Lu 2006a Details of maintenance immunosuppression not available.
Lupo 2008 Not on maintenance immunosuppression
Margarit 2005 Not on maintenance immunosuppression
McDiarmid 1991 Not on maintenance immunosuppression
McDiarmid 1991a Not on maintenance immunosuppression
McDiarmid 1993 Includes paediatric population undergoing liver transplants
Moench 2007 Not on maintenance immunosuppression
Mor 1994 Includes paediatric population undergoing liver transplants
Nashan 1996 Not on maintenance immunosuppression
Neuberger 2009 No fixed immunosuppression regimen in either intervention group or control group, or both
Neuhaus 1993 Not a randomised clinical trial
Neuhaus 1994 No fixed immunosuppression regimen in either intervention group or control group, or both
Neuhaus 1997 No fixed immunosuppression regimen in either intervention group or control group, or both
Neuhaus 2000 Not on maintenance immunosuppression
Neuhaus 2002 Not on maintenance immunosuppression
Neumann 2012 Not on maintenance immunosuppression
Nevens 2007 Randomisation was performed after development of renal impairment
Northup 2006 Details of maintenance immunosuppression not available.
Otero 2009 Not on maintenance immunosuppression
Pageaux 1995 Not on maintenance immunosuppression
Pageaux 2006 Randomisation was performed after development of renal impairment
Pascher 2015 Details of maintenance immunosuppression not available.
Ramirez 2013 Not on maintenance immunosuppression
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Reding 1993 Not on maintenance immunosuppression
Reggiani 2005 Not on maintenance immunosuppression
Reich 2005 Randomisation was performed after development of renal impairment
Saliba 2016 Details of maintenance immunosuppression not available.
Saliba 2016a Comparison of different regimens of same drug
Salizzoni 2001 Not clear whether the immunosuppressive regimens were continued beyond the induction phase
Schiano 2006 Not on maintenance immunosuppression
Schmeding 2007 Not on maintenance immunosuppression
Schmeding 2011 No fixed immunosuppression regimen in either intervention group or control group, or both
Shaked 2016 Randomisation was performed at an average of 17 months after liver transplantation
Shenoy 2007 Randomisation was performed at least 6 months after transplantation only in people with renal
dysfunction
Simone 2008 No fixed immunosuppression regimen in either intervention group or control group, or both
Studenik 2005 Not on maintenance immunosuppression
Takada 2013 Not on maintenance immunosuppression
Teperman 2013 No fixed immunosuppression regimen in either intervention group or control group, or both
Therapondos 2002 Details of maintenance immunosuppression not available.
Timmermann 2002 Details of maintenance immunosuppression not available.
Tisone 1998 Not on maintenance immunosuppression
Trune ka 2015 Not on maintenance immunosuppression
Villamil 2014 Randomisation was performed at least 6 months after liver transplantation
Washburn 2001 Not on maintenance immunosuppression
Washburn 2008 Not on maintenance immunosuppression
Watson 2007 Randomisation was performed after development of renal impairment
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Wiesner 2001 No fixed immunosuppression regimen in either intervention group or control group, or both
Yoshida 2005 Not on maintenance immunosuppression
Characteristics of ongoing studies [ordered by study ID]
Nashan 2015
Trial name or title Hephaistos (NCT01551212)
Methods Randomised clinical trial
Participants People undergoing liver transplantation
Interventions Everolimus plus tacrolimus versus tacrolimus
Outcomes Graft loss, death, adverse events
Starting date January 2012
Contact information nashan@uke.de
Notes Trial registration: NCT01551212
Simone 2014
Trial name or title REFLECT
Methods Randomised clinical trial
Participants People undergoing liver transplantation
Interventions Everolimus plus tacrolimus versus tacrolimus
Outcomes Graft loss, death
Starting date March 2014
Contact information Novartis Pharmaceuticals (+41613241111)
Notes Trial registration: NCT02115113
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D A T A A N D A N A L Y S E S
This review has no analyses.
A D D I T I O N A L T A B L E S
Table 1. Characteristics of included studies (arranged by comparisons)
Study name Num-
ber of par-
ticipants ran-
domised
Postran-
domisation
dropouts
Num-
ber of par-
ticipants for
whom out-
come was re-
ported
Intervention
1
Intervention
2
Intervention
3
Average
follow-up pe-
riod
(months)
Belli 1998 108 - 108 Cyclosporine
A
plus glucocor-
ticosteroids
Cyclosporine
A
- 41
Pageaux 2004 174 0 174 Cyclosporine
A
plus glucocor-
ticosteroids
Cyclosporine
A
- 6
Masetti 2010 78 0 78 Everolimus Cyclosporine
A
- 22
Sterneck 2000 57 - 57 Cyclosporine
A plus my-
cophenolate
plus glucocor-
ticosteroids
Cyclosporine
A plus aza-
thioprine
plus glucocor-
ticosteroids
- 6
De Simone
2012
719 0 719 Tacrolimus
plus
everolimus
Everolimus Tacrolimus 36
Baiocchi 2006 20 0 20 Cyclosporine
A
Tacrolimus - 3
Cholongitas
2011
66 0 66 Cyclosporine
A
Tacrolimus - 97
Fernandez-
Miranda 1998
27 - 27 Cyclosporine
A
Tacrolimus - 22
Fung 1991 81 - 81 Cyclosporine
A
Tacrolimus - 12
Greig 2003 143 0 143 Cyclosporine
A
Tacrolimus - 12
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Table 1. Characteristics of included studies (arranged by comparisons) (Continued)
Loinaz 2001 101 1 100 Cyclosporine
A
Tacrolimus - 24
O’Grady
2002
606 0 606 Cyclosporine
A
Tacrolimus - 36
Shenoy 2008 60 0 60 Cyclosporine
A
Tacrolimus - 12
Stegall 1997 71 0 71 Cyclosporine
A
Tacrolimus - 6
Zervos 1998 50 1 49 Cyclosporine
A
Tacrolimus - 14
Chen 2002 81 0 81 Cyclosporine
A plus aza-
thioprine
Tacrolimus - 124
Jonas 2005 121 0 121 Cyclosporine
A plus aza-
thioprine
Tacrolimus - 144
Manousou
2014
103 1 97 Tacrolimus
plus azathio-
prine
Tacrolimus - 96
Boudjema
2011
195 0 195 Tacrolimus
plus my-
cophenolate
plus glucocor-
ticosteroids
Tacrolimus - 11
Asrani 2014 222 0 222 Tacrolimus
plus sirolimus
Tacrolimus - 24
Pham 1998 88 8 76 Cyclosporine
A plus aza-
thioprine
plus glucocor-
ticosteroids
Tacrolimus
plus glucocor-
ticosteroids
- 27
Porayko 1994 37 0 37 Cyclosporine
A plus aza-
thioprine
plus glucocor-
ticosteroids
Tacrolimus
plus glucocor-
ticosteroids
- 12
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Table 1. Characteristics of included studies (arranged by comparisons) (Continued)
Martin 2004 85 6 79 Cyclosporine
A
plus glucocor-
ticosteroids
Tacrolimus
plus glucocor-
ticosteroids
- 12
Jain 2001 350 0 350 Tacrolimus
plus my-
cophenolate
plus glucocor-
ticosteroids
Tacrolimus
plus glucocor-
ticosteroids
- 34
Fisher 1998 99 0 99 Cyclosporine
A plus my-
cophenolate
Tacrolimus
plus my-
cophenolate
- 48
Pelletier 2013 100 0 100 Tacrolimus
plus my-
cophenolate
plus glucocor-
ticosteroids
Tacrolimus
plus my-
cophenolate
- 69
Table 2. Potential effect modifiers
Study
name
Inter-
vention
1
Inter-
vention
2
Primary
trans-
planta-
tion
Rea-
son for
trans-
planta-
tion:
hep-
atitis C
virus
Rea-
son for
trans-
planta-
tion:
hep-
atitis B
virus
Rea-
son for
trans-
planta-
tion: al-
coholic
cirrho-
sis
Rea-
son for
trans-
planta-
tion:
other
reasons
Years of
ran-
domisa-
tion
Addi-
tional
drug
used for
induc-
tion
Average
follow-
up in
months
Risk of
bias
Belli
1998
Cy-
closporine
A plus
gluco-
corticos-
teroids
Cy-
closporine
A
104/104
(100.
0%)
42/104
(40.4%)
24/104
(23.1%)
9/104
(8.7%)
21/104
(20.2%)
1991 to
1995
Yes 41 High
Pageaux
2004
Cy-
closporine
A plus
gluco-
corticos-
teroids
Cy-
closporine
A
174/174
(100.
0%)
26/174
(14.9%)
12/174
(6.9%)
84/174
(48.3%)
52/174
(29.9%)
1999 to
2001
Yes 6 High
Masetti
2010 Everolimus
Cy-
closporine
78/
78 (100.
Not
stated
Not
stated
Not
stated
Not
stated
2006 to
2008
Yes 22 High
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Table 2. Potential effect modifiers (Continued)
A 0%)
Sterneck
2000
Cy-
closporine
A plus
my-
cophe-
nolate
plus
gluco-
corticos-
teroids
Cy-
closporine
A plus
azathio-
prine
plus
gluco-
corticos-
teroids
57/
57 (100.
0%)
Not
stated
Not
stated
Not
stated
Not
stated
1996 to
1998
No 6 High
De
Simone
2012
Tacrolimus
plus
everolimus
Inter-
ven-
tion 1:
Everolimus
Inter-
ven-
tion 2:
Tacrolimus
719/719
(100.
0%)
175/719
(24.3%)
49/719
(6.8%)
171/719
(23.8%)
258/719
(35.9%)
2008 to
2011
Yes 36 High
Baiocchi
2006
Cy-
closporine
A
Tacrolimus
20/
20 (100.
0%)
8/20
(40.0%)
4/20
(20.0%)
3/20
(15.0%)
1/20 (5.
0%)
Not
stated
No 3 High
Cholon-
gitas
2011
Cy-
closporine
A
Tacrolimus
66/
66 (100.
0%)
Not
stated
Not
stated
Not
stated
Not
stated
1996 to
1997
No 97 High
Fernan-
dez-
Miranda
1998
Cy-
closporine
A
Tacrolimus
Not
stated
Not
stated
Not
stated
Not
stated
Not
stated
1993 to
1995
Yes 22 High
Fung
1991
Cy-
closporine
A
Tacrolimus
81/
81 (100.
0%)
Not
stated
0/81 (0.
0%)
Not
stated
Not
stated
1990 Yes 12 High
Greig
2003
Cy-
closporine
A
Tacrolimus
139/143
(97.2%)
47/143
(32.9%)
0/143
(0.0%)
25/143
(17.5%)
67/143
(46.9%)
1996 Yes 12 High
Loinaz
2001
Cy-
closporine
A
Tacrolimus
100/100
(100.
0%)
Not
stated
Not
stated
Not
stated
Not
stated
Not
stated
Yes 24 High
O’Grady
2002
Cy-
closporine
A
Tacrolimus
606/606
(100.
0%)
60/606
(9.9%)
20/606
(3.3%)
110/606
(18.2%)
98/606
(16.2%)
1997 to
1999
Yes 36 High
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Table 2. Potential effect modifiers (Continued)
Shenoy
2008
Cy-
closporine
A
Tacrolimus
Not
stated
32/60
(53.3%)
5/60 (8.
3%)
8/60
(13.3%)
16/60
(26.7%)
2002 to
2004
Yes 12 High
Stegall
1997
Cy-
closporine
A
Tacrolimus
Not
stated
Not
stated
0/71 (0.
0%)
Not
stated
Not
stated
Not
stated
Yes 6 High
Zervos
1998
Cy-
closporine
A
Tacrolimus
Not
stated
49/
49 (100.
0%)
0/49 (0.
0%)
0/49 (0.
0%)
0/49 (0.
0%)
1995 to
1996
Yes 14 High
Chen
2002
Cy-
closporine
A plus
azathio-
prine
Tacrolimus
81/
81 (100.
0%)
2/81 (2.
5%)
2/81 (2.
5%)
6/81 (7.
4%)
71/81
(87.7%)
1990 to
1992
No 124 High
Jonas
2005
Cy-
closporine
A plus
azathio-
prine
Tacrolimus
121/121
(100.
0%)
35/121
(28.9%)
30/121
(24.8%)
20/121
(16.5%)
37/121
(30.6%)
1990 to
1992
Yes 144 High
Manousou
2014
Tacrolimus
plus
azathio-
prine
Tacrolimus
97/
97 (100.
0%)
97/
97 (100.
0%)
0/97 (0.
0%)
0/97 (0.
0%)
0/97 (0.
0%)
2000 to
2007
Yes 96 High
Boud-
jema
2011
Tacrolimus
plus my-
cophe-
nolate
plus
gluco-
corticos-
teroids
Tacrolimus
195/195
(100.
0%)
16/195
(8.2%)
4/195
(2.1%)
83/195
(42.6%)
91/195
(46.7%)
2003 to
2007
Yes 11 High
Asrani
2014 Tacrolimus
plus
sirolimus
Tacrolimus
222/222
(100.
0%)
72/222
(32.4%)
30/222
(13.5%)
79/222
(35.6%)
40/222
(18.0%)
2000 to
2003
Yes 24 High
Pham
1998
Cy-
closporine
A plus
azathio-
Tacrolimus
plus
gluco-
76/
76 (100.
0%)
Not
stated
Not
stated
Not
stated
Not
stated
1990 to
1992
No 27 High
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Table 2. Potential effect modifiers (Continued)
prine
plus
gluco-
corticos-
teroids
corticos-
teroids
Porayko
1994
Cy-
closporine
A plus
azathio-
prine
plus
gluco-
corticos-
teroids
Tacrolimus
plus
gluco-
corticos-
teroids
37/
37 (100.
0%)
Not
stated
Not
stated
6/37
(16.2%)
29/37
(78.4%)
1990 to
1991
No 12 High
Martin
2004
Cy-
closporine
A plus
gluco-
corticos-
teroids
Tacrolimus
plus
gluco-
corticos-
teroids
79/
79 (100.
0%)
79/
79 (100.
0%)
0/79 (0.
0%)
0/79 (0.
0%)
0/79 (0.
0%)
Not
stated
Yes 12 High
Jain
2001 Tacrolimus
plus my-
cophe-
nolate
plus
gluco-
corticos-
teroids
Tacrolimus
plus
gluco-
corticos-
teroids
350/350
(100.
0%)
95/350
(27.1%)
15/350
(4.3%)
70/350
(20.0%)
160/350
(45.7%)
1995 to
1998
No 34 High
Fisher
1998
Cy-
closporine
A plus
my-
cophe-
nolate
Tacrolimus
plus my-
cophe-
nolate
99/
99 (100.
0%)
37/99
(37.4%)
7/99 (7.
1%)
11/99
(11.1%)
44/99
(44.4%)
1995 to
1997
Yes 48 High
Pelletier
2013 Tacrolimus
plus my-
cophe-
nolate
plus
gluco-
corticos-
teroids
Tacrolimus
plus my-
cophe-
nolate
100/100
(100.
0%)
54/100
(54.0%)
Not
stated
42/100
(42.0%)
8/100
(8.0%)
2002 to
2005
No 69 High
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Table 3. Risk of bias (arranged by intervention)
Name of
studies
Interven-
tion 1
Interven-
tion 2
Random
sequence
genera-
tion
Alloca-
tion con-
cealment
Blinding
of partic-
ipants
and
health
profes-
sionals
Blinding
of out-
come as-
sessors
Attrition
bias
Selec-
tive out-
come re-
porting
For-
profit
bias
Over-
all risk of
bias
Belli
1998
Cy-
closporine
A plus
gluco-
corticos-
teroids
Cy-
closporine
A
Unclear Unclear Unclear Unclear Unclear Low Unclear High
Pageaux
2004
Cy-
closporine
A plus
gluco-
corticos-
teroids
Cy-
closporine
A
Unclear Unclear Low Low Low Low High High
Masetti
2010 Everolimus
Cy-
closporine
A
Unclear Unclear High High Low Low Unclear High
Sterneck
2000
Cy-
closporine
A plus
my-
copheno-
late plus
gluco-
corticos-
teroids
Cy-
closporine
A plus
azathio-
prine plus
gluco-
corticos-
teroids
Unclear Unclear Unclear Unclear Unclear Low High High
De
Simone
2012
Tacrolimus
plus
everolimus
Interven-
tion 1:
Everolimus
Interven-
tion 2:
Tacrolimus
Unclear Unclear High High Low Low High High
Baiocchi
2006
Cy-
closporine
A
Tacrolimus
Unclear Unclear Unclear Unclear Low High Unclear High
Cholon-
gitas
2011
Cy-
closporine
A
Tacrolimus
Low Low High High Low Low Unclear High
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Table 3. Risk of bias (arranged by intervention) (Continued)
Fernan-
dez-
Miranda
1998
Cy-
closporine
A
Tacrolimus
Unclear Unclear Unclear Unclear Unclear High Unclear High
Fung
1991
Cy-
closporine
A
Tacrolimus
Low Low Unclear Unclear Unclear Low Low High
Greig
2003
Cy-
closporine
A
Tacrolimus
Unclear Unclear High High Low Low High High
Loinaz
2001
Cy-
closporine
A
Tacrolimus
Unclear Unclear High High Unclear Low Unclear High
O’Grady
2002
Cy-
closporine
A
Tacrolimus
Low Low High High Low Low High High
Shenoy
2008
Cy-
closporine
A
Tacrolimus
Unclear Unclear Unclear Unclear Low Low High High
Stegall
1997
Cy-
closporine
A
Tacrolimus
Unclear Unclear High High Low Low Unclear High
Zervos
1998
Cy-
closporine
A
Tacrolimus
Unclear Unclear Unclear Unclear Unclear Low Unclear High
Chen
2002
Cy-
closporine
A plus
azathio-
prine
Tacrolimus
Unclear Unclear High High Low High High High
Jonas
2005
Cy-
closporine
A plus
azathio-
prine
Tacrolimus
Unclear Unclear High High Low Low High High
Manousou
2014
Tacrolimus
plus aza-
thioprine
Tacrolimus
Low Low Unclear Unclear High Low High High
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Table 3. Risk of bias (arranged by intervention) (Continued)
Boud-
jema
2011
Tacrolimus
plus my-
copheno-
late plus
gluco-
corticos-
teroids
Tacrolimus
Low Low High High Low Low Low High
Asrani
2014 Tacrolimus
plus
sirolimus
Tacrolimus
Low Unclear High High Low Low High High
Pham
1998
Cy-
closporine
A plus
azathio-
prine plus
gluco-
corticos-
teroids
Tacrolimus
plus
gluco-
corticos-
teroids
Unclear Unclear High High High High Unclear High
Porayko
1994
Cy-
closporine
A plus
azathio-
prine plus
gluco-
corticos-
teroids
Tacrolimus
plus
gluco-
corticos-
teroids
Unclear Unclear High High Low Low High High
Martin
2004
Cy-
closporine
A plus
gluco-
corticos-
teroids
Tacrolimus
plus
gluco-
corticos-
teroids
Low Low High High High Low High High
Jain 2001
Tacrolimus
plus my-
copheno-
late plus
gluco-
corticos-
teroids
Tacrolimus
plus
gluco-
corticos-
teroids
Low Low High High Low Low Unclear High
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